


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 7 : C07D 211/52, 211/58, 471/10, 401/04, A61K 31/445 // (C07D 471/10, 235:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/06545 (43) International Publication Date: 10 February 2000 (10.02.00)</p>
<p>(21) International Application Number: PCT/US99/14165 (22) International Filing Date: 26 July 1999 (26.07.99) (30) Priority Data: 09/122,878 27 July 1998 (27.07.98) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: TULSHIAN, Deen; 4 Saddle Ridge Drive, Lebanon, NJ 08833 (US). HO, Ginny, D.; 42 Chestnut Hill Drive, Murray Hill, NJ 07974 (US). SILVERMAN, Lisa, S.; 214 Hana Road, Edison, NJ 08817 (US). MATASI, Julius, J.; 129 Spruce Mill Lane, Scotch Plains, NJ 07076 (US). McLEOD, Robbie, L.; 13 Creek Trail, Branchburg, NJ 08876 (US). HEY, John, A.; 122 Hopper Avenue, Nutley, NJ 07110 (US). CHAPMAN, Richard, W.; 30 Ditmars Circle, Somerville, NJ 08876 (US). BERCOVICI, Ana; 1 Howell Drive, West Orange, NJ 07052 (US). CUSS, Francis, M.; 14 Byrom Drive, Basking Ridge, NJ 07920 (US).</p>		<p>(74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Department, K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.</p>
<p>(54) Title: HIGH AFFINITY LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1</p> <div style="text-align: center;">  <p>(I)</p> </div>		
<p>(57) Abstract</p> <p>Compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond; X¹ is optionally substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X² is -CHO, -CN, optionally substituted amino, alkyl, or aryl; or X¹ is optionally substituted benzofused heterocyclyl and X² is hydrogen; or X¹ and X² together form an optionally benzofused spiro heterocyclyl group; R¹, R², R³ and R⁴ are independently H and alkyl, or (R¹ and R⁴) or (R² and R³) or (R¹ and R³) or (R² and R⁴) together can form an alkylene bridge of 1 to 3 carbon atoms; Z¹ is optionally substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or -CO₂(alkyl or substituted amino) or CN; Z² is H or Z¹; Z³ is H or alkyl; or Z¹, Z² and Z³, together with the carbon to which they are attached, form bicyclic saturated or unsaturated rings; pharmaceutical compositions therefore, and the use of said compounds as nociceptin receptor inhibitors useful in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

HIGH AFFINITY LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1

10 BACKGROUND

The nociceptin receptor ORL-1 has been shown to be involved with modulation of pain in animal models. ORL-1 (the nociceptin receptor) was discovered as an "orphan opioid-like receptor" i.e. a receptor whose ligand was unknown. The nociceptin receptor is a G protein coupled receptor. While highly related in structure to the three classical opioid receptors, i.e. the targets for traditional opioid analgesics, it is not activated by endogenous opioids. Similarly, endogenous opioids fail to activate the nociceptin receptor. Like the classical opioid receptors, the nociceptin receptor has a broad distribution in the central nervous system.

In late 1995, nociceptin was discovered and shown to be an endogenous peptide ligand that activates the nociceptin receptor. Data included in the initial publications suggested that nociceptin and its receptor are part of a newly discovered pathway involved in the perception of painful stimuli. Subsequent work from a number of laboratories has shown that nociceptin, when administered intraspinally to rodents, is an analgesic. The efficacy of nociceptin is similar to that of endogenous opioid peptides. Recent data has shown that nociceptin acts as an anxiolytic when administered directly into the brain of rodents. When tested in standard animals models of anxiety, the efficacy of nociceptin is similar to that seen with classical benzodiazapine anxiolytics. These data suggest that a small molecule agonist of the nociceptin receptor could have significant analgesic or anxiolytic activity.

Additional recent data (Rizzi, et al, Life Sci. 64, (1999), p. 157-163) has shown that the activation of nociceptin receptors in isolated guinea pig bronchus inhibits tachykinergic non adrenergic-non


cholinergic contraction, indicating that nociceptin receptor agonists could be useful in the treatment of asthma. Also, it has been reported (Ciccocioppo et al, Psychopharmacology, 141 (1999), p. 220-224) nociceptin reduces the rewarding properties of ethanol in msP alcohol preferring rats, suggesting that intervention of nociceptin could be useful in the treatment of alcohol abuse. In EP 856,514, 8-substituted 1,3,8-triazaspiro[4,5]decan-4-on derivatives were disclosed as agonists and/or antagonists of orphanin FQ (i.e., nociceptin) useful in the treatment of various disorders, including depression; 2-oxoimidazole derivatives disclosed in WO98/54168 were described as having similar utility. Earlier, benzimidazolyl piperidines were disclosed in U.S. 3,318,900 as having analgesic activity.

Potent analgesic agents such as traditional opioids, e.g. morphine, carry with them significant side-effects. Clinically relevant side-effects include tolerance, physical dependence, respiratory depression and a decrease in gastrointestinal motility. For many patients, particularly those subjected to chronic opioid therapy, i.e. cancer patients, these side effects limit the dose of opioid that can be administered. Clinical data suggests that more than one-third of cancer patients have pain which is poorly controlled by present agents. Data obtained with nociceptin suggest the potential for advantages over opioids. When administered chronically to rodents, nociceptin, in contrast to morphine, showed no addiction liability. Additionally, chronic morphine treatment did not lead to a "cross-tolerance" to nociceptin, suggesting that these agents act via distinct pathways.

In view of the current interest in pain relief, a welcome contribution to the art would be additional compounds useful for modifying the effect of nociceptin, a natural ligand to ORL-1 and therefore useful in the management of pain and anxiety. Such a contribution is provided by this invention.

SUMMARY OF THE INVENTION

Compounds of the present invention are represented by formula I



or a pharmaceutically acceptable salt or solvate thereof, wherein:

the dotted line represents an optional double bond;


X¹ is R⁵-(C₁-C₁₂)alkyl, R⁶-(C₃-C₁₂)cycloalkyl, R⁷-aryl, R⁸-

5 heteroaryl or R¹⁰-(C₃-C₇)heterocycloalkyl;

X² is -CHO, -CN, -NHC(=NR²⁶)NHR²⁶, -CH(=NOR²⁶), -NHOR²⁶, R⁷-aryl, R⁷-aryl(C₁-C₆)alkyl, R⁷-aryl(C₁-C₆)alkenyl, R⁷-aryl(C₁-C₆)alkynyl, -(CH₂)_vOR¹³, -(CH₂)_vCOOR²⁷, -(CH₂)_vCONR¹⁴R¹⁵, -(CH₂)_vNR²¹R²² or -(CH₂)_vNHC(O)R²¹, wherein v is zero, 1, 2 or 3 and


10 wherein q is 1 to 3 and a is 1 or 2;

or X¹ is




and X² is hydrogen;

15 or X¹ and X² together form a spiro group of the formula



m is 1 or 2;

n is 1, 2 or 3, provided that when n is 1, one of R¹⁶ and R¹⁷ is -C(O)R²⁸;

R^{11} is independently selected from the group consisting of H, R^5 -(C_1 - C_6)alkyl, R^6 -(C_3 - C_{12})cycloalkyl, -(C_1 - C_6)alkyl(C_3 - C_{12})cycloalkyl, -(C_1 - C_6)alkyl-OR¹⁹, -(C_1 - C_6)alkyl-NR¹⁹R²⁰ and $-(CH_2)_q-N$  _a, wherein q and a are as defined above;

R¹³ is H, (C₁-C₆)alkyl, R⁷-aryl, -(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰; -(C₁-C₆)alkyl-SR¹⁹; or aryl (C₁-C₆) alkyl;

5 R^{14} and R^{15} are independently selected from the group

consisting of H, R⁵-(C₁-C₆)alkyl, R⁷-aryl and
wherein q and a are as defined above:


R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, R⁵-(C₁-C₆)alkyl, R⁷-aryl, (C₃-C₁₂)cycloalkyl, R⁸-heteroaryl, R⁸-heteroaryl(C₁-C₆)alkyl, -C(O)R²⁸, -(C₁-C₆)alkyl(C₃-C₇)-heterocycloalkyl, -(C₁-C₆)alkyl-OR¹⁹ and -(C₁-C₆)alkyl-SR¹⁹;

R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, aryl and aryl(C₁-C₆)alkyl;

15 R²¹ and R²² are independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, (C₃-C₁₂)cycloalkyl(C₁-C₆)alkyl, (C₃-C₇)heterocycloalkyl, -(C₁-C₆)alkyl(C₃-C₇)-heterocycloalkyl, R⁷-aryl, R⁷-aryl(C₁-C₆)alkyl, R⁸-heteroaryl(C₁-C₁₂)alkyl, -(C₁-C₆)alkyl-OR¹⁹, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -(C₁-C₆)alkyl-SR¹⁹, -(C₁-C₆)alkyl-NR¹⁸-
20 (C₁-C₆)alkyl-O-(C₁-C₆)alkyl and -(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl-NR¹⁸-(C₁-C₆)alkyl;

R¹⁸ is hydrogen or (C₁-C₆)alkyl;

25 Z¹ is R⁵-(C₁-C₁₂)alkyl, R⁷-aryl, R⁸-heteroaryl, R⁶-(C₃-C₁₂)cycloalkyl, R¹⁰-(C₃-C₇)heterocycloalkyl, -CO₂(C₁-C₆)alkyl, CN or -C(O)NR¹⁹R²⁰; Z² is hydrogen or Z¹; Z³ is hydrogen or (C₁-C₆)alkyl; or Z¹, Z² and Z³, together with the carbon to which they are attached, form the group



that the sum of w and u is 1-3; c and d are independently 1 or 2; s is 1 to 5; and ring A is a fused R⁷-phenyl or R⁸-heteroaryl ring;

R²³ is 1 to 3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ and
 5 -(C₁-C₆)alkyl-NR¹⁹R²⁰;


R²⁴ is 1 to 3 substituents independently selected from the group consisting of R²³, -CF₃, -OCF₃, NO₂ or halo, or R²⁴ substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

10 R²⁵ is 1-3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, (C₁-C₆)alkoxy and halo;


R²⁶ is independently selected from the group consisting of H, (C₁-C₆)alkyl and R²⁵-C₆H₄-CH₂-;

R²⁷ is H, (C₁-C₆)alkyl, R⁷-aryl(C₁-C₆)alkyl, or (C₃-C₁₂)cycloalkyl;

15 R²⁸ is (C₁-C₆)alkyl, -(C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl, R⁷-aryl, R⁷-aryl-(C₁-C₆)alkyl, R⁸-heteroaryl, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -(C₁-C₆)alkyl-OR¹⁹ or -(C₁-C₆)alkyl-SR¹⁹;




provided that when X¹ is or X¹ and X² together are




and Z¹ is R⁷-phenyl, Z² is not hydrogen or (C₁-C₃)alkyl;

20 provided that when Z¹, Z² and Z³, together with the carbon to which they are attached, form




or

, and X¹ and X² together are



, R¹¹ is not H, (C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl or (C₁-C₆)hydroxyalkyl;

25 provided that when R² and R⁴ form an alkylene bridge, Z¹, Z² and Z³, together with the carbon to which they are attached, are not




provided that when X¹ is and Z¹ is R⁶-(C₃-C₁₂)-cycloalkyl, Z² is not H.


5 Preferred compounds of the invention are those wherein Z¹ and Z² are each R⁷-aryl, particularly R⁷-phenyl. Preferred R⁷ substituents are (C₁-C₆)alkyl and halo, with ortho-substitution being more preferred.

Compounds wherein R¹, R², R³ and R⁴ are each hydrogen are preferred, as well as compounds wherein R¹ and R³ are each hydrogen and R² and R⁴ are an alkylene bridge of 2 or 3 carbons.

10 Preferred are compounds wherein X¹ is R⁷-aryl, for example R⁷-phenyl, and X² is OH (i.e., X² is -(CH₂)_vOR¹³, wherein v is 0 and R¹³ is



H) or -NC(O)R²⁸, compounds wherein X¹ is is hydrogen and R¹¹ is (C₁-C₆)alkyl, -(C₁-C₆) alkyl(C₃-C₁₂)cycloalkyl, 15 -(C₁-C₆)alkyl-OR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R²⁰; and compounds wherein X¹ and X² together form the spirocyclic group



, wherein m is 1, R¹⁷ is phenyl and R¹¹ is -(C₁-C₆)alkyl-OR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R², or (C₁-C₆)-alkyl -N^(C₁-C₆)_a

20 In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier.

The compounds of the present invention are agonists and/or antagonists of the ORL-1 receptor, and therefore, in another aspect, the


invention relates to a method of treating pain, anxiety, cough, asthma, alcohol abuse or depression, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I.

In another aspect, the invention relates to a method of treating
5 cough, comprising administering to a mammal in need of such treatment:
(a) an effective amount of a nociceptin receptor ORL-1 agonist; and (b)
an effective amount of a second agent for treating cough, allergy or
asthma symptoms selected from the group consisting of: antihistamines,
5-lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β-
10 adrenergic receptor agonists, xanthine derivatives, α-adrenergic
receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁,
NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists.

In still another aspect, the invention relates to a pharmaceutical
composition comprising a nociceptin receptor ORL-1 agonist and a
15 second agent selected from the group consisting of: antihistamines, 5-
lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β-
adrenergic receptor agonists, xanthine derivatives, α-adrenergic
receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁,
NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists.

20 In other words, the invention relates to the use of compounds of
claim 1 in the treatment of pain, anxiety, cough, asthma, alcohol abuse
or depression, and to the use of a nociceptin receptor ORL-1 agonist,
alone or in combination with a second agent for treating cough, allergy
or asthma symptoms.

25 In yet another aspect, the present invention relates to a novel
compound not included in the structure of formula I, said compound
being:



30 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the effect in guinea pigs of Compounds A and B (see Example 12) compared to baclofen on capsaicin-induced cough.

Figures 2A and 2B show changes in Tidal Volume after administration of Compound A or baclofen, and Figure 2C shows changes in frequency of breaths after administration of Compound A or baclofen.

5

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following terms are used as defined below unless otherwise indicated:

10 M^+ represents the molecular ion of the molecule in the mass spectrum and MH^+ represents the molecular ion plus hydrogen of the molecule in the mass spectrum;

Bu is butyl; Et is ethyl; Me is methyl; and Ph is phenyl;

alkyl (including the alkyl portions of alkoxy, alkylamino and dialkylamino) represents straight and branched carbon chains
15 containing from 1 to 12 carbon atoms or 1 to 6 carbon atoms; for example methyl, ethyl, propyl, iso-propyl, n-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like;

alkenyl represents an alkyl chain of 2 to 6 carbon atoms comprising one or two double bonds in the chain, e.g., vinyl, propenyl or
20 butenyl;

alkynyl represents an alkyl chain of 2 to 6 carbon atoms comprising one triple bond in the chain, e.g., ethynyl or propynyl;

alkoxy represents an alkyl moiety covalently bonded to an adjacent structural element through an oxygen atom, for example,
25 methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like;

aryl (including the aryl portion of arylalkyl) represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is phenyl), wherein said aryl group optionally can be fused with aryl, (C₃-C₇)cycloalkyl, heteroaryl or
30 hetero(C₃-C₇)cycloalkyl rings; and wherein R⁷-aryl means that any of the available substitutable carbon and nitrogen atoms in said aryl group and/or said fused ring(s) is optionally and independently substituted, and wherein the aryl ring is substituted with 1-3 R⁷ groups. Examples of aryl groups are phenyl, naphthyl and anthryl;

arylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been substituted with one to three aryl groups; wherein aryl is as defined above;


aryloxy represents an aryl group, as defined above, wherein
5 said aryl group is covalently bonded to an adjacent structural element through an oxygen atom, for example, phenoxy;

cycloalkyl represents saturated carbocyclic rings of from 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms; wherein R⁶-cycloalkyl means that any of the available substitutable carbon atoms in said
10 cycloalkyl group is optionally and independently substituted, and wherein the cycloalkyl ring is substituted with 1-3 R⁶ groups;

cycloalkylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms of the alkyl moiety have been substituted with one to three cycloalkyl groups, wherein cycloalkyl is as
15 defined above;



halo represents fluoro, chloro, bromo and iodo;

heteroaryl represents cyclic groups having one to three heteroatoms selected from O, S and N, said heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized
20 pi electrons to provide aromatic character, with the aromatic heterocyclic groups containing from 5 to 14 carbon atoms, wherein said heteroaryl group optionally can be fused with one or more aryl, cycloalkyl, heteroaryl or heterocycloalkyl rings; and wherein any of the available substitutable carbon or nitrogen atoms in said heteroaryl group and/or
25 said fused ring(s) may be optionally and independently substituted, and wherein the heteroaryl ring can be substituted with 1-3 R⁸ groups; representative heteroaryl groups can include, for example, furanyl, thienyl, imidazolyl, pyrimidinyl, triazolyl, 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl N-oxide wherein pyridyl N-oxide can be represented as:




30

heteroarylalkyl represents an alkyl group, as defined above, wherein one or more hydrogen atoms have been replaced by one or more heteroaryl groups, as defined above;

heterocycloalkyl represents a saturated ring containing from 3 to 7 carbon atoms, preferably from 4 to 6 carbon atoms, interrupted by 1 to 3 heteroatoms selected from -O-, -S- and -NR²¹-, wherein R²¹ is as defined above, and wherein optionally, said ring may contain one or two unsaturated bonds which do not impart aromatic character to the ring; and wherein any of the available substitutable carbon atoms in the ring may substituted, and wherein the heterocycloalkyl ring can be substituted with 1-3 R¹⁰ groups; representative heterocycloalkyl groups include 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 1-, 2-, 3- or 4-piperidiny, 2- or 3-pyrrolidiny, 1-, 2- or 3-piperiziny, 2- or 4-dioxany, morpholiny,  or  wherein R¹⁷ is as defined above and t is 0, 1 or 2.

When the optional double bond in the piperidiny ring of formula I is present, one of X¹ and X² forms the bond with the 3-position carbon and the remaining X¹ or X² is not hydrogen.

When X¹ and X² form a spiro group as defined above, the wavy lines in the structures shown in the definition indicate the points of attachment to to the 4-position carbon of the piperidiny ring, e.g., compounds of the following formulas are formed:



Certain compounds of the invention may exist in different stereoisomeric forms (e.g., enantiomers, diastereoisomers and atropisomers) . The invention contemplates all such stereoisomers both in pure form and in mixture, including racemic mixtures.

25 Certain compounds will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically

acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.


Certain basic compounds also form pharmaceutically acceptable salts, e.g., acid addition salts. For example, pyrido-nitrogen atoms may
5 form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well
10 known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia
15 and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention.

All such acid and base salts are intended to be pharmaceutically
20 acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

Compounds of the invention can be prepared by known methods from starting materials either known in the art or prepared by methods
25 known in the art. Examples of general procedures and specific preparative examples are given below.

Typically, X¹,X²-substituted piperidines are alkylated with Z¹,Z²,Z³-substituted halomethanes in the presence of excess bases such as K₂CO₃ and Et₃N, in solvents such as DMF, THF or CH₃CN, at
30 room temperature or at elevated temperatures.

X¹,X²-substituted piperidines are either commercially available or made by known procedures. For example, 4-hydroxy-4-phenylpiperidine can be converted to a 4-*t*Boc-amino-4-phenylpiperidine according to the following reaction scheme, wherein Bn is benzyl, Ph is
35 phenyl and *t*Boc is t-butoxycarbonyl:




Commercially available 4-phenyl-4-piperidinol is protected with a benzyl group and the resulting intermediate is then treated with Me₃SiCN. The resultant amide is hydrolyzed with aqueous HCl in CH₃OH to produce the 4-amino compound. The amino group is protected with tBoc and the N-benzyl group is removed by hydrogenolysis to produce the desired 4-amino-piperidine derivative.


The 4-(protected)amino-piperidine then can be reacted with a Z¹,Z²,Z³-halomethane and the protecting group removed. The amine (i.e., X² is -NH₂) can undergo various standard conversions to obtain amine derivatives. For example, the amine of formula I can be reacted with a R²²-carboxaldehyde in the presence of a mild reducing agent such as Na(OAc)₃BH or with a compound of the formula R²²-L, wherein L is a leaving group such as Cl or Br, in the presence of a base such as Et₃N.

An alternative method for preparing compounds of formula I wherein X¹ is R⁷-aryl and X² is OH involves alkylating a 4-piperidone hydrochloride with a Z¹,Z²,Z³-halomethane, then reacting the ketone with an appropriately substituted R⁷-phenylmagnesium bromide or with a compound of the formula X¹-L¹, wherein L¹ is Br or I, and n-butyl-lithium.

X¹,X²-substituted compounds of formula I can be converted into other compounds of formula I by performing reactions well known in the art on the X¹ and/or X² substituents. For example, a carboxaldehyde-substituted piperidine (i.e., X² is -CHO) can be converted to a substituted piperidine wherein X² is R¹³-O-CH₂-, as shown in the following procedure for a compound of formula I wherein X¹ is phenyl, Z¹ and Z² are each phenyl, and R¹, R², R³ and R⁴, and Z³ are H :



- 5 A cyano-substituted piperidine (i.e., X² is -CN) can be converted to a substituted piperidine wherein X² is R²¹R²²N-CH₂- or X² is R²⁸C(O)NH-CH₂-, as shown in the following procedure for a compound of formula I wherein X¹ is phenyl, R²¹, R¹, R², R³ and R⁴, and Z³ are H, and L is a leaving group such as Cl or Br:




- 10 Compounds of formula I wherein X¹ is a benzofused nitrogen-containing heterocycle having an R¹¹ substituent other than hydrogen are prepared by reacting the corresponding compounds wherein R¹¹ is hydrogen with a compound of the formula R¹¹L (R¹¹ is not H, and L is as defined above).

- 15 Alternatively, X¹,X²-substituted piperidine starting materials can be converted into other X¹,X²-substituted piperidines by similar procedures before reacting with the Z¹,Z²,Z³-substituted halomethane.


For compounds of formula I wherein R¹, R², R³ and R⁴ variously form alkylene bridges, commercially available N-protected 4-

piperidones are treated with phenyl lithium and resulting intermediate is deprotected to produce the desired compounds, for example:



wherein Pr is a N-protecting group, Ph is phenyl and z is 1-2.

- 5 The Z¹,Z²,Z³-halomethyl derivatives wherein Z¹ and Z² are R⁷-phenyl are either commercially available or can be prepared using the procedure shown in the following reaction scheme:




- 10 Similar procedures, or others known in the art, can be used to prepare compounds wherein the Z substituents are other than phenyl.


Compounds of the present invention and preparative starting materials thereof, are exemplified by the following examples, which should not be construed as limiting the scope of the disclosure.

- 15 The following solvents and reagents are referred to herein by the abbreviations indicated: tetrahydrofuran (THF); ethanol (EtOH); methanol (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc); N,N-dimethylformamide (DMF); and diethyl ether (Et₂O). Room temperature is abbreviated as rt.

Example 1




A mixture of 4-hydroxy-4-phenyl piperidine (1.5 g, 8.47 mmol) and K_2CO_3 (3.0 g, 21.73 mmol) in CH_3CN was stirred at rt. To this was added α -bromo-diphenylmethane (2.5 g, 10.12 mmol) and the reaction was stirred overnight. The reaction mixture was concentrated, redissolved in CH_2Cl_2 , washed with water, dried ($MgSO_4$) and concentrated. Chromatography (SiO_2 , 9:1 hexane/EtOAc) gave the title compound (2.6g, 90%). 1H NMR ($CDCl_3$): δ 1.80 (m, 2H), 2.25 (m, 2H), 2.42 (m, 2H), 2.90 (m, 2H), 4.40 (s, 1H), 7.2-7.6 (m, 15H).


Example 2

Step 1: A solution of 4-piperidone monohydrate hydrochloride (5 g, 32.6 mmol) in CH_3CN was alkylated using the procedure described in Example 1. Chromatography of the residue on silica (95:5 hexane/EtOAc) gave the desired compound.


Step 2: 4-Methylphenylmagnesium bromide (0.5 M in THF, 1.75 ml, 0.87 mmol) was added to a solution of product of Step 1 (191 mg, 0.72 mmol) in THF dropwise at $0^\circ C$. The solution was stirred at 0° for 2h, quenched with ice- H_2O , extracted with EtOAc, washed with H_2O and brine, dried, and concentrated. Chromatography of the residue on silica (95:5 hexane/EtOAc, 93:7 hexane/EtOAc) gave the title compound (0.091 g, 30%). 1H NMR ($CDCl_3$) δ 7.5 (m, 6H, ArH), 7.3 (t, 4H, ArH), 7.2 (t, 4H, ArH), 4.35 (s, 1H), 2.8 (d, 2H), 2.4 (m, 5H), 2.2 (td, 2H), 1.75 (d, 2H); MS (CI) 358 (M+1); Elemental analysis for $C_{25}H_{27}NO \cdot 1.2 H_2O$: calcd: C 79.2, H 7.82, N 3.69; observed: C 78.90, H 8.02, N 3.85.

Example 3

- Add n-BuLi (2.5 M, 0.38 ml, 0.95 mmol) to a solution of 3-bromothiophene (0.15g, 0.95 mmol) in Et₂O dropwise at -70°C and stir for 2h. Add a solution of the product of Step 1 of Example 2 (230 mg, 0.87 mmol) in Et₂O (4 ml) to the reaction mixture, slowly warm to rt over a period of 3 h, quench with ice-cooled NH₄Cl (aq), extract with Et₂O, wash with H₂O and brine, dry, and concentrate. Chromatograph the residue (95:5 hexane/EtOAc) to give the title compound (90 mg). ¹H NMR (CDCl₃) δ 7.5 (d, 2H), 7.35 (bt, 4H), 7.25 (m, 3H), 7.2 (m, 2H), 4.4 (s, 1H), 2.8 (d, 2H), 2.5 (t, 2H), 2.3 (dt, 2H), 2.0 (d, 2H); MS (CI) 350 (M+1); Elemental analysis for C₂₂H₂₂NO₃·1.1 HCl·0.9 H₂O: calcd: C 65.11, H 6.43, N 3.54, S 7.8, Cl 9.61; observed: C 65.27, H 6.54, N 3.45, S 7.30, Cl 9.43.


Example 4

- Step 1:** 4-Phenyl-4-piperidinecarboxaldehyde (1.0 g, 5.29 mM) was alkylated using the procedure of Example 1, Step 1, to obtain the desired product (1.69g, 90%). ¹H NMR (CDCl₃): δ 2.40 (m, 4H), 2.50 (m, 2H), 2.85 (m, 2H), 4.25 (s, 1H), 7.20-7.50 (m, 15H), 9.42 (s, 1H).
- Step 2:** A solution of the product from Step 1 (3.0 g, 8.45 mmol) was cooled to 0°C and treated with NaBH₄ (1.0 g, 26.32 mmol). After 0.5 h, reaction mixture was treated with 1N HCl and concentrated. The residue was extracted with CH₂Cl₂, dried (MgSO₄) and evaporated. Column chromatography on the residue (4:1 hexane:EtOAc) produced desired primary alcohol. ¹H NMR (CDCl₃): δ 2.00 (m, 2H), 2.25 (m, 4H), 2.65 (m, 2H), 3.65 (d, 2H), 4.20 (s, 1H), 4.25 (d, 1H), 7.2-7.6 (m, 15H).
- Step 3:** The product of Step 2 was treated with NaH in DMF at 0°C for 0.5h. CH₃I was added and reaction was warmed up to rt. After stirring overnight, the reaction mixture was poured on ice, extracted with Et₂O, dried (MgSO₄) and evaporated. Column chromatography on the residue produced the title compound. ¹H NMR (CDCl₃): δ 2.10 (m, 4H), 2.40 (m, 2H), 2.78 (m, 2H), 2.90 (m, 2H), 3.00(s, 3H), 4.38 (s, 1H), 7.21-7.52 (m, 15H).


Example 5

- Step 1:** A solution of 4-cyano-4-phenylpiperidine hydrochloride (5.0 g, 22.4 mM) in DMF (30 ml) was treated with Et₃N (7.20 ml, 47 mM) and bromodiphenylmethane (6.38 g, 25.80 mM) and stirred at rt under N₂ for 20h. The reaction mixture was concentrated in vacuo and partitioned between EtOAc and H₂O. The organic layer was washed with twice with water, then brine, and dried (MgSO₄), filtered and concentrated. Chromatography (SiO₂, 19:1 hexane/EtOAc) gave 6.0 g (76%) of the desired product. ¹H NMR (CDCl₃): δ 2.21 (m, 4H), 2.49 (t, J=12.3Hz, 2H), 3.11 (d, J=12.5 Hz, 2H), 4.46 (s, 1H), 7.45 (m, 15H).
- Step 2:** A solution of the product (6.0 g, 17 mM) of Step 1 in Et₂O (40 ml) was cooled to 0°C and treated with a 1M solution of LAH (34.10 ml, 34 mM), dropwise, under N₂, over 0.5 h. The reaction mixture was allowed to warm to rt and then refluxed for 4h. The reaction mixture was cooled to 0°C and treated with water (8 eq.). The reaction mixture was allowed to warm to rt and was stirred for 1 h. The resultant solid was filtered off and rinsed with Et₂O, and the filtrate was concentrated to yield 5.45 g (90%) of desired product. ¹H NMR (CD₃OD): δ 1.84 (m, 2H), 2.16 (m, 4H), 2.56 (m, 2H), 2.68 (m, 2H), 4.07 (s, 1H), 7.25 (m, 15H).
- Step 3:** A solution of the product (0.2 g, 0.56 mM) of Step 2 in CH₂Cl₂ (3 ml) was treated with benzoyl chloride (0.078 ml, 0.673 mM) and pyridine (0.045g, 0.568 mM) at rt for 18 h under N₂. The reaction mixture was concentrated, then partitioned between H₂O and CH₂Cl₂. The organic layer was washed with water (2x) and brine, then dried (MgSO₄), filtered and concentrated. Chromatography (SiO₂, 3:1 hexane/EtOAc) gave 0.2 g (77%) of the desired product. ¹H NMR (CD₃OD): δ 2.13 (m, 6H), 2.66 (m, 4H), 3.50 (s, 2H), 4.07 (s, 1H), 7.11-7.65 (m, 20H).
- Step 4:** A solution of the product (0.075 g, 0.16 mM) of Step 3 in THF (3 ml) was cooled to 0°C with stirring. LAH (solid, 0.025 g, 0.65 mM) was added under N₂ and stirring was continued for 0.25h. The reaction mixture was then refluxed for 5 h, then stirred at rt for 18h. The reaction

mixture was cooled to 0°C and quenched with water (8 eq). The reaction mixture was allowed to warm to rt and was stirred for 1 h. The resultant solid was filtered off and rinsed with Et₂O, the filtrate was dried (MgSO₄) and concentrated. Chromatography (neutral Al₂O₃, CH₂Cl₂, then 3:1 CH₂Cl₂:EtOAc) gave 0.014 g (20%) of the title compound. ¹H NMR (CD₃OD): δ 1.90 (m, 2H), 2.15 (m, 4H), 2.48 (m, 2H), 2.68 (s, 2H), 3.53 (s, 2H), 4.05 (s, 1H), 7.01-7.38 (m, 20H).

Example 6

The product of Example 5, Step 2 (0.2 g, 0.561 mM), acetic anhydride (3 ml) and Et₃N (0.096 ml, 0.67 mM) were combined and stirred at rt for 18h. The reaction mixture was concentrated and partitioned between H₂O and CH₂Cl₂. The organic layer was washed with water (2x), brine, then dried (MgSO₄), filtered and concentrated to give 0.214 g (95%) of the title compound. ¹H NMR (CD₃OD): δ 1.87 (m, 5H), 2.16 (m, 4H), 2.61 (m, 2H), 3.31 (s, 2H), 4.07 (s, 1H), 7.12-7.40 (m, 20H).

Example 7

Step 1: A solution of 4-phenyl-4-hydroxy piperidine (10.0 g, 56.4 mM) in DMF (60 ml) was treated with Et₃N (8.28 ml, 59.2 mM) and benzyl bromide (7.37 ml, 62.10 mM) and stirred at rt under N₂ for 20 h. The reaction mixture was concentrated in vacuo, basified to pH 8 with saturated NaHCO₃ and partitioned between EtOAc and H₂O. The organic layer was washed twice with water, then brine, and dried (MgSO₄), filtered and concentrated. Chromatography (neutral Al₂O₃, hexane, then 1:1 hexane:EtOAc) gave 11.95 g (80%) of the desired product.

- Step 2: To a mixture of the product (30.0 g, 0.112 mol) of Step 1 and $(\text{CH}_3)_3\text{SiCN}$ (59.94 ml, 0.448 mol), cooled to -15°C in an ethylene glycol/ CO_2 bath, under N_2 , is added glacial AcOH (47 ml) dropwise, while maintaining an internal temperature of -15°C . Concentrated
- 5 H_2SO_4 (47 ml, 0.34 M) is added dropwise, with vigorous stirring, while maintaining an internal temperature of -15°C . The cooling bath was then removed and reaction mixture was stirred at rt for 18h. The reaction mixture was poured on ice and adjusted to pH 7 with a 50% NaOH solution while maintaining a temperature of 25°C . The reaction mixture
- 10 was then extracted with CH_2Cl_2 , and the organic layer was washed with water (2x), then brine, and dried (MgSO_4), filtered and concentrated. Recrystallization with EtOAc /hexane (1:10) gave 22.35 g (68%) of desired compound. ^1H NMR (CD_3OD): δ 2.10 (m, 2H), 2.40 (m, 4H), 2.82 (d, $J=11.50$ Hz, 2H), 3.57 (s, 2H), 7.20-7.43 (m, 10H), 8.05 (s, 1H).
- 15 Step 3: The product of Step 2 (20 g, 67.9 mM) and 5% (w/w) concentrated HCl (aq)/ CH_3OH (350 ml) were stirred under N_2 for 48 h. The mixture was concentrated to yield a foam which was suspended in Et_2O and concentrated to remove excess HCl . The resultant solid was resuspended in Et_2O , collected by vacuum filtration, washed with Et_2O
- 20 and dried under vacuum to give (23 g, 100%) of desired product. ^1H NMR (CD_3OD) of di- HCl salt: δ 2.59 (t, $J=13.3$ Hz, 2H), 2.93 (t, $J=13.3$ Hz, 2H), 3.07 (d, $J=13.50$ Hz, 2H), 3.58 (d, $J=13$ Hz, 2H), 4.26 (s, 2H), 7.56 (m, 10H).
- Step 4: The product of Step 3 (24.10 g, 71 mM), CH_2Cl_2 (300 ml),
- 25 $(\text{tBoc})_2\text{O}$ (17.0 g, 78.1 mM) and Et_3N (14.37 g, 0.142 M) were combined and stirred under N_2 , at rt, for 18hrs. The reaction mixture was partitioned between CH_2Cl_2 and H_2O , and the aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were washed with water (2x), then brine, and dried (MgSO_4), filtered and concentrated.
- 30 The resulting solid was suspended in Et_2O and sonicated, filtered and dried to produce the desired compound (21.98 g, 90%). ^1H NMR (CD_3OD): δ 1.09 (bs, 2H), 1.39 (s, 1H), 2.05 (m, 2H), 2.34 (m, 4H), 2.65 (d, $J=11.8$ Hz, 2H), 3.56 (s, 2H), 7.18-7.40 (m, 10H).
- Step 5: The product of Step 4 (5.22 g, 14.2 mM), CH_3OH (430 ml).
- 35 $\text{Pd}(\text{OH})_2/\text{C}$ (3.0 g) and NH_4COOH (18.86 g, 0.298 M) were combined


and refluxed under N₂ for 8h. The reaction mixture was filtered using celite, washing with CH₃OH. The combined filtrates were concentrated to produce (3.90 g, 97%) of the desired product. ¹H NMR (CD₃OD): δ 1.10 (bs, 2H), 1.39 (s, 7H), 1.90 (m, 2H), 2.26 (m, 4H), 2.92 (m, 4H), 7.17-7.41 (m, 5H).

Step 6: The product of Step 5 (2.74 g, 9.91 mM), CH₃CN (85 ml), Et₃N (1.75 ml, 12.40 mM) and bromodiphenylmethane (2.70 g, 10.9 mM) were combined and stirred at rt under N₂ for 18hrs. The mixture was concentrated and the resultant residue was partitioned between H₂O and EtOAc. The EtOAc layer was washed with water (2x), brine, then dried (MgSO₄), filtered and concentrated. Chromatography (neutral Al₂O₃, hexane, then 4:1 hexane:EtOAc) gave 2.85 g (65%) of the desired product. ¹H NMR (CD₃OD): δ 1.07 (bs, 2H), 1.37 (s, 7H), 2.23 (m, 2H), 2.24 (m, 4H), 2.74 (d, J= 12.1 Hz, 2H), 4.27 (s, 1H), 7.10-7.47 (m, 15H).

Step 7: The product of Step 6 (4.6 g, 10 mM), 1,4-dioxane (38 ml) and 4 M HCl in 1,4-dioxane (25 ml, 101 mM) were combined and stirred at rt under N₂ for 4 h. The mixture was concentrated and the residue was suspended in Et₂O and re-concentrated. The resultant solid was resuspended in Et₂O, sonicated and the product was collected by vacuum filtration and dried to give 3.27 g (80% of the desired product). ¹H NMR (CD₃OD) of di-HCl salt: δ 2.91(m, 8H), 5.34 (s, 1H), 7.37-7.77 (m, 15H).


Step 8: To a suspension of the product of Step 7 (0.3 g, 0.722 mM) in CH₂Cl₂ (3 ml), under N₂ at rt, was added 2-thiophenecarboxaldehyde (0.133 ml, 1.44 mM). The pH of the reaction was adjusted to 6 with Et₃N and the mixture was stirred for 0.5 h. Na(OAc)₃BH (0.230 g, 1.08 mM) was then added and the reaction mixture was stirred at rt under N₂ for 3 h. The reaction was quenched with saturated NaHCO₃(aq) and partitioned between Et₂O and H₂O. The organic layer was washed with H₂O (2x), brine, dried (MgSO₄), filtered and concentrated.

Chromatography (SiO₂, toluene, then 1:19 EtOAc: toluene) gave 0.158 g (50%) of the desired product. ¹H NMR (CD₃OD): δ 1.96 (m, 2H), 2.17 (m, 2H), 2.52 (m, 4H), 3.45 (s, 2H), 4.24 (s, 1H), 6.76 (d, J=3.5 Hz, 1H), 6.85 (dd, J=3.6 Hz, 1H), 7.13-7.50 (m, 16H).

Example 8

Step 1: Alkylate a solution of 4-(2-oxo-1-benzimidazolyl)-piperidine in CH_3CN using the procedure described in Step 1 of Example 1 to produce the desired compound.

Step 2: Add NaH to a solution of 3-[1-(diphenylmethyl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazo-1-one (2.5 g, 6.6 mmol) in DMF (25 ml) and stir at rt for 1 h. Add n-butyl iodide to the mixture at rt and stir overnight. Quench with ice- H_2O , extract with EtOAc, wash with H_2O and brine, dry (MgSO_4) and concentrate. Chromatograph the residue on silica (1:9 EtOAc/hexane) to give the title compound (2.35 g). Dissolve the title compound in Et_2O , add HCl in Et_2O (8 ml, 1 M), stir for 1 h and filter to give the HCl salt. ^1H NMR (CDCl_3) δ 7.55 (m, 4H, ArH), 7.35 (m, 5H, ArH), 7.25 (m, 2H, ArH), 7.15 (m, 2H, ArH), 7.1 (m, 1H, ArH), 4.4 (m, 2H), 3.95 (t, 2H), 3.15 (d, 2H), 2.6 (dq, 2H), 2.1 (t, 2H, 1.8, m, 4H), 1.5 (m, 2H), 1.0 (t, 3H); ESI-MS 440 ($\text{M}+1$); Elemental analysis for $\text{C}_{29}\text{H}_{33}\text{N}_3\text{O}\cdot\text{HCl}\cdot\text{H}_2\text{O}$: calcd: C 70.5, H 7.3, N 8.5, Cl 7.18; observed: C 70.48, H 7.28, N 8.49, Cl 7.49).

Example 9


20

Add SOCl_2 (247 mg, 2.07 mmol) to a solution of 2-(chlorophenyl)phenylmethanol (300 mg, 1.38 mmol) in CH_2Cl_2 at rt, stir at rt for 5 h and concentrate. Dissolve the residue in CH_3CN , add K_2CO_3 , 4-hydroxy-4-phenylpiperidine and NaI. Stir the solution at reflux overnight, filter and concentrate. Chromatograph the residue on silica (9:1 hexane/EtOAc) to give the title compound. ^1H NMR (CDCl_3) δ 7.91 (d, 1H), 7.58 (d, 2H), 7.54 (d, 2H), 7.42 (t, 2H), 7.32 (m, 5H), 7.26 (t, 3H), 7.16 (t, 3H), 5.0 (s, 1H), 2.8 (dd, 2H), 2.5 (dq, 2H), 2.2 (dt, 2H), 1.75 (d,

25

2H). Dissolve the title compound in ether, add HCl/Et₂O (1 M) to give the HCl salt. MS CI (378 (M+1); Elemental analysis for C₂₄H₂₄NOCl.HCl.0.2H₂O: calcd: C 68.97, H 6.13, N 3.35, Cl 16.96; observed: C 68.87, H 6.04, N 3.35, Cl 17.00.


5

Example 10

Step 1: Alkylate a solution of 4-piperidone monohydrate hydrochloride (880 mg, 5 mmol) in CH₃CN with mandelonitrile (1 g, 7.51 mmol) using the procedure described in Example 9. Chromatography of the residue on silica followed by recrystallization (EtOAc) gives the desired compound (630 mg).

Step 2: Add a solution of 2-methoxyphenylmagnesium bromide in THF (24 ml, 0.5 M, 11.85 mmol) to a solution of the product of Step 1 (330 mg, 1.185 mmol) in THF at 0°C. Remove the ice-bath and stir the reaction mixture at reflux for 6 h. Quench the reaction with NH₄Cl (aq), extract with EtOAc, wash with brine, dry and concentrate. Chromatograph the residue (95:5, 9:1 hexane/EtOAc) to give the title compound (330 mg). ¹H NMR (CDCl₃) δ 7.76 (d, 1H), 7.62 (d, 1H), 7.55 (d, 1H), 7.45 (t, 1H), 7.34 (m, 3H), 7.24 (m, 2H), 7.03 (t, 1H), 6.90 (d, 2H), 4.88 (s, 1H), 3.89 (s, 3H), 2.94 (d, 1H), 2.82 (d, 1H), 2.45 (td, 2H), 2.26 (t, 2H), 1.78 (d, 2H). Dissolve the title compound in Et₂O, add HCl in Et₂O, stir for 1 h and filter to give the HCl salt. MS FAB 374.1 (M+1); elemental analysis for C₂₅H₂₇NO₂.HCl.0.15H₂O: calcd: C 72.77, H 6.91, N 3.39, Cl 8.59; observed: C 72.76, H 7.02, N 3.59, Cl 8.83.

25


Example 11

Step 1 Alkylate a solution of 1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (0.5g) in CH₃CN using the procedure described in Step 1 of Example 1 to produce desired compound.

- Step 2 Alkylate the product from Step 1, 1-phenyl-8-(diphenylmethyl)-1,3,8-triazaspiro[4,5]decan-4-one (0.4 g) with CH₃I using the procedure described in Step 2 of Example 1 to produce the title compound (0.25 g).
¹H NMR (CDCl₃) δ 1.70 (d, 2H), 2.85 (m, 6H), 3.05(s, 3H), 4.50 (s, 1H), 4.72 (s, 2H), 6.95 (t, 1H), 7.05(d 2H), 7.20-7.60 (m, 12H).











- 10 Using the procedures of Examples 1 to 11, employing the appropriate starting material, compounds shown in the following tables are prepared.













Table 1



- 15 wherein X¹ is as defined below:

X ¹	Physical Data
H	C ₂₄ H ₂₅ N FAB 283.3 (100), 167.2 (52)
OMe	C ₂₅ H ₂₇ NO FAB 358 (80), 167 (70)
OEt	C ₂₆ H ₂₉ NO:HCl FAB 342 (67) 167 (100)
	C ₂₇ H ₃₁ NO ESI 386.1 (79), 167 (100)
	C ₃₁ H ₃₁ NO:HCl ESI 434.2 (62), 167 (100)
CN	C ₂₅ H ₂₄ N ₂ FAB 353.2 (53), 275.10 (24).
CHO	C ₂₅ H ₂₅ NO CI 356 (28), 167 (100)
CH ₂ OH	C ₂₅ H ₂₇ NO CI 358.1 (37), 167 (100)

	C ₃₂ H ₃₃ NO:HCl FAB 448.1 (46), 167.2 (100)
CH ₂ OMe	C ₂₅ H ₂₇ NO FAB 357.10 (10), 167 (100)
CH ₂ OEt	C ₂₆ H ₂₉ NO CI 373.3 (12), 372(42), 167 (100)
	C ₃₀ H ₃₄ NO CI 440.25 (33), 439.2 (100), 167.2 (89)
CH ₂ NH ₂	C ₂₅ H ₂₈ N ₂ :2HCl ESI 357.10 (37), 167 (100)
CH ₂ NHCOCH ₃	C ₂₇ H ₃₀ N ₂ O ESI 399.1 (53), 167.0 (100)
	C ₃₂ H ₃₂ N ₂ O FAB 462.1(15), 461.1(41), 393 (8)
	C ₃₂ H ₃₄ N ₂ :HCl ESI447.1 (100), 281.1 (29)
	C ₃₃ H ₃₂ N ₂ F ₃ :HCl ESI 515(100), 349.10 (33), 167 (49)
CH ₂ NHCH ₂ CH ₃	C ₂₇ H ₃₂ N ₂ :HCl ESI 385.1(100), 219.10 (26), 167 (76)
	C ₂₉ H ₃₆ N ₂ O:HCl CI 429 (53), 351 (100) 327 (13), 167 (34)
	C ₂₈ H ₃₂ N ₂ O ₂ CI 429 (100),351 (9), 261 (11), 167 (81)
	C ₂₈ H ₃₄ N ₂ O:HCl CI 415(100), 327 (33), 167 (65)
	C ₃₁ H ₃₉ N ₃ O:HCl ESI 470 (100), 304 (51), 259 (16), 167 (46)
	C ₃₁ H ₄₁ N ₃ :HCl ESI 456 (100), 290 (11), 167 (11)

	$C_{30}H_{30}N_2O_2$ ESI 451(100), 283 (8), 167 (94)
	$C_{34}H_{43}N_3O:HCl$ ESI 510 (88), 344 (73), 167 (100)
	$C_{32}H_{41}N_3:HCl$ ESI 468 (98), 302 (22), 167 (100)
	$C_{31}H_{31}N_3O:HCl$ CI 462(100), 384 (4), 167 (45)
	$C_{30}H_{32}N_2O:Cl$ ESI 437 (100), 271 (11), 167 (41)
	$C_{30}H_{32}N_2O:HCl$ ESI 437 (87), 271 (7), 167 (100)
	$C_{30}H_{32}N_2S:HCl$ ESI 453 (92), 167 (100)
	$C_{30}H_{32}N_2S:HCl$ ESI 453 (100), 287 (6), 167 (78)
	$C_{32}H_{36}N_2S:HCl$ ESI 481 (69), 340 (5), 167 (100)
	$C_{29}H_{36}N_2S:HCl$ ESI 445 (100), 399 (3), 279 (11), 167 (84)
	$C_{29}H_{33}N_2F_3:HCl$ ESI 467 (69), 167 (100)
CH_2NMe_2	$C_{27}H_{32}N_2:HCl$ FAB 385.3 (100), 219.2 (6), 162.2 (77)
NH_2	$C_{24}H_{26}N_2:HCl$ ESI 343 (48), 326 (70), 167 (100)
$NH(CH_2)_3NEt_2$	$C_{31}H_{41}N_3:HCl$ ESI 456 (72), 326 (74), 167 (100)
	$C_{29}H_{30}N_2O:HCl$ CI 423 (60), 326 (100), 167 (74)





































	C ₃₁ H ₃₉ N ₃ :HCl ESI 454(76), 326 (60), 167 (100)
	C ₂₉ H ₃₀ N ₂ S:HCl FAB 439 (90), 326 (25), 167 (100)
NHMe	C ₂₅ H ₂₈ N ₂ :HCl ESI 357 (20), 326 (87), 167 (100)
NMe ₂	C ₂₆ H ₃₀ N ₂ :HCl ESI 371 (11), 326 (81), 167 (100)

Table 2

wherein X¹ is as defined below

X ¹	Physical Data
	C ₂₄ H ₂₅ NO FAB 343.1 (13), 342.1 (26)
	C ₂₄ H ₂₄ BrNO ESI 424 (20) 422 (18) 167-2 (92)
	C ₂₄ H ₂₄ NOCl CI 363 (43), 362 (22), 167.20 (100)
	C ₂₄ H ₂₄ FNO 361 (22), 167.2 (75)
Benzyl	C ₂₅ H ₂₇ NO CI 358.1 (62), 167 (78)
n-Propyl-phenyl	C ₂₇ H ₃₁ NO:HCl FAB 386.1 (46), 167 (100)
	C ₂₅ H ₂₃ NOF ₃ Cl EI 369 (3), 368 (14), 167 (100)
	C ₂₅ H ₂₄ F ₃ NO FAB 413(31), 412 (57), 167 (100)

	$C_{25}H_{27}NO_2$ CI 374.45(M+1), 266.30 (39%), 167.25 (100%)
	$C_{26}H_{30}N_2O$ FAB 387 (86%), 369 (22%)
	$C_{25}H_{26}NOF$ FAB 376.2 (68%), 375.2 (32%), 358.20 (6)
	$C_{25}H_{27}NO_2$ CI 374.45 (58%), 375.45 (27), 356.35 (29)
	$C_{24}H_{24}ClNO$ CI 378.35 (31%), 377.35 (18%), 360.30 (22)
	$C_{25}H_{27}NO$ CI 358.35 (68), 357.35 (38), 340.35 (47), 167.25 (100)
	$C_{24}H_{23}F_2NO$ CI 380.35(28%), 379.35 (22), 362.35 (23), 167.25 (100)
	$C_{25}H_{27}NO$ CI 358.35 (63), 357.35 (43), 340.35 (53), 167.25 (100)
	$C_{25}H_{27}NO$ CI 358.35 (49), 357.35 (41), 340.35 (35), 167.25 (100)
	$C_{24}H_{24}FNO$ CI 362.35 (41), 361.35 (218), 344.35 (39), 167.25 (100)
	$C_{26}H_{25}NO$ FAB 368(37), 367 (38), 366(100), 290 (41)
	$C_{25}H_{27}NSO$ FAB 375 (10), 374.20 (40), 306.7 (13)
	$C_{25}H_{27}NSO$ FAB 390 (22), 389(27), 388 (100), 312 (48)
	$C_{24}H_{23}NOF_2$ 380.2 (11), 379.2 (16), 378.2 (31)
	$C_{26}H_{29}NO$ CI 373.45 (22), 372.40 (82), 354.35 (60), 167.25 (100)

	$C_{24}H_{31}NO$ FAB 350.3 (4), 349.3 (7), 348.9 (17)
n Hexyl	$C_{24}H_{33}NO$ FAB 352 (85), 274 (189)
n propyl	$C_{27}H_{31}NO$ ESI 386 (70), 167 (100)
n butyl	$C_{28}H_{33}NO$ ESI 400.1 (68), 167 (100)
	$C_{21}H_{25}NO:HCl$ ESI 308.1 (32), 167.0 (100)
	$C_{22}H_{23}NO_2:HCl$ CI 334.25 (34), 333.25 (26), 316.25 (41), 167.25 (100)
	$C_{22}H_{23}NOS:HCl$ CI 350.25 (32), 349.35 (24), 332.25 (41), 167.25 (100)
	$C_{22}H_{23}NOS:HCl$ CI 350.25 (27), 349.35 (18), 332.25 (20), 167.25 (100)
	$C_{23}H_{24}N_2O:HCl$ ESI 345.1 (68), 167 (100)
	$C_{22}H_{23}NO_2$ CI 334.25 (37), 333.25 (24), 316.25 (31), 167.25 (100)
	$C_{25}H_{24}N_2O:HCl$ FAB 369.3 (3), 368.3 (6), 367.3 (13)
	$C_{21}H_{27}NO:HCl$ CI 310.40 (38), 309.40 (25), 292.40 (33), 167.25 (100)
	$C_{24}H_{24}NOF:HCl$ FAB 362.1 (100), 232.1 (11)
	$C_{22}H_{29}NO:HCl$ FAB 324.30 (100)
	$C_{21}H_{25}NO:HCl$ CI 308.2 (64), 307.2 (30), 290.2 (57), 167.25 (100)



















	C ₂₃ H ₂₅ NOS:HCl CI 364.15 (69), 346.15 (71), 167.25 (100)
	C ₂₁ H ₂₂ N ₂ SO:HCl CI 351.1 (52), 350.1 (8), 266.15 (12), 167.2 (100)
	C ₂₇ H ₂₈ N ₂ O:HCl FAB 397.2 (80), 167.2 (100)
	C ₂₅ H ₂₈ N ₂ O:HCl ESI 373.1 (28), 167 (100)
	C ₂₅ H ₂₇ NO ₂ :HCl ESI 374.1 (43), 167 (100)

Table 3

wherein Z¹ and Z² are as defined below:

Z ¹	Z ²	Physical Data
		C ₂₄ H ₂₄ NOCl CI 380 (30), 378.1 (100), 201 (100)
		C ₂₄ H ₂₃ NOF ₂ CI 380.15 (79), 379.15 (47), 362.05 (100)
		C ₂₃ H ₂₄ N ₂ O:HCl ESI 345.1(69), 327.1 (49), 168 (100)
		C ₂₃ H ₂₄ N ₂ O:HCl ESI 345.1 (58), 168 (100)
		C ₂₅ H ₂₇ NO:HCl CI 358.20 (60), 340.20 (51), 181.25 (100)
		C ₂₄ H ₂₄ NOBr:HCl ESI 424.1 (17), 422 (17), 247.1 (100), 245.1 (99)

		$C_{25}H_{27}NO:HCl$ ESI 358.1(32.70), 181 (100)
		$C_{24}H_{24}NOCl:HCl$ CI 380.10 (30), 378.15 (100)
		$C_{26}H_{29}NO:HCl$ ESI 372.1 (24), 195.1 (100)
		$C_{25}H_{27}NO:HCl$ ESI 358.1 (48%), 181.1 (100)
		$C_{25}H_{24}ONF_3:HCl$ ESI 412.1 (56), 235 (100)
		$C_{25}H_{24}ONF_3:HCl$ ESI 412.1 (73), 235.1 (100)
		$C_{26}H_{29}NO:HCl$ ESI 372.1 (39), 195.1 (100)
		$C_{24}H_{24}NOBr:HCl$ ESI 424.10 (48), 422.1(47), 245.1 (100)
		$C_{22}H_{23}NOS:HCl$ ESI 350.1 (31), 173 (100)
		$C_{25}H_{24}ONF_3:HCl$ ESI 412.1 (54), 235.10 (100)
		$C_{24}H_{24}NOF:HCl$ ESI 362.1 (23), 185.1 (100)
		$C_{24}H_{23}NOF_2:HCl$ CI 380.15 (100), 362.15 (89), 203.25 (99)
		$C_{24}H_{23}NOCl_2:HCl$ ESI 416.1 (7), 414 (32), 412 (45), 235.1 (100)
		$C_{25}H_{24}N_2O_2F_2:HCl$ FAB 423.2 (100), 218.0 (18)









































































		$C_{24}H_{23}NOF_2 \cdot HCl$ CI 380.15 (79), 379.15 (45), 362.05 (100)
		$C_{26}H_{29}NO_2 \cdot HCl$ FAB 388.3 (100), 266.1 (15)
		$C_{25}H_{27}NO_2 \cdot HCl$ FAB 374.1 (100), 197 (73)
		$C_{24}H_{24}NOCl \cdot HCl$ FAB 380.1(27), 378.2 (80), 201.0 (100)
		$C_{25}H_{27}NO \cdot HCl$ ESI 358.1 (15), 181.1 (100)
Methyl		$C_{19}H_{23}NO \cdot HCl$ ESI 282.1 (100), 160.0 (84.5)
Ethyl		$C_{20}H_{25}NO \cdot HCl$ ESI 296.1 (100), 160.0 (84)
		$C_{21}H_{27}NO \cdot HCl$ ESI 310.1 (100), 160.1 (52)
		$C_{22}H_{29}NO \cdot HCl$ ESI 324.1(100), 160.1 (52)
		$C_{23}H_{31}NO \cdot HCl$ CI 338.3 (100), 266.20 (77), 160.35 (17)
		$C_{24}H_{33}NO \cdot HCl$ ESI 352.1 (100), 160.0 (41.83)
		$C_{23}H_{29}NO \cdot HCl$ ESI 336.1 (66.39), 160.0 (63), 159 (100)
		$C_{23}H_{30}N_2O_2 \cdot HCl$ ESI 367.1 (35), 190 (100)
		$C_{23}H_{31}NO \cdot HCl$ ESI 338.1 (100), 161.0 (36), 160 (70)

Table 4







































wherein X¹, X², Z¹ and Z² are as defined below

X ¹	X ²	Z ¹	Z ²	Physical Data
	NH ₂			C ₂₂ H ₃₀ N ₂ :HCl ESI 323(71), 306 (100), 160(31)
				C ₂₇ H ₃₄ N ₂ S:HCl ESI 419 (23), 306 (100)
	CH ₂ NH ₂			C ₂₃ H ₃₂ N ₂ :HCl ESI 337 (96), 174 (100), 160 (19)
				C ₂₈ H ₃₆ N ₂ S:HCl ESI 433 (100), 320 (65), 174 (58)
	NH ₂			C ₂₅ H ₂₈ N ₂ :HCl CI 357 (47), 340 (24), 279 (8), 181(100)
				C ₂₈ H ₃₆ N ₂ S:HCl ESI 433 (100), 320 (42), 174 (77)
				C ₃₀ H ₃₂ N ₂ S:HCl ESI 453 (24), 340(27), 181 (100)
	NH ₂			C ₂₆ H ₃₀ N ₂ :HCl ESI 371 (16) 195 (100)
				C ₃₁ H ₃₄ N ₂ S:HCl ESI 467 (25), 354 (30), 195 (100)
	NH ₂			C ₂₄ H ₂₄ N ₂ Cl ₂ :HCl ESI 413 (18), 411 (26), 396 (39), 394 (51), 237 (69), 235 (100)
	OH			C ₂₆ H ₂₈ BrNO:HCl 450 (12), 195.1 (100)


	OH			C ₂₆ H ₂₈ FNO:HCl ESI 390.1 (9.6), 195.1 (100)
	OH			C ₂₆ H ₂₈ ClNO:HCl 407.1 (5), 195.1 (100) 406.1 (16)
				C ₃₁ H ₃₂ N ₂ OS ESI 481 (25), 195 (100)
				C ₂₈ H ₃₂ N ₂ O Cl 413(31), 354 (8), 195 (100)
				C ₂₉ H ₂₈ Cl ₂ N ₂ S:HCl ESI 509 (10), 507 (14), 396 (56), 394 (77), 237 (68), 235 (100)
	OH			C ₂₅ H ₂₆ N ₂ OC ₂ :HCl ESI 443(42), 441 (56), 425 (31), 235 (100)
				C ₃₀ H ₃₆ N ₂ OS ESI 473 (39), 195 (100)
				C ₃₃ H ₃₄ N ₂ O ESI 475 (41), 195 (100)
				C ₂₉ H ₃₄ N ₂ O ₂ ESI 443(31), 195 (100)
				C ₃₀ H ₃₄ N ₂ O:HCl ESI 439 (17), 195 (100)
				C ₃₄ H ₄₂ N ₂ O:HCl ESI 495 (30), 195 (100)
				C ₃₃ H ₃₆ N ₂ :HCl ESI 461 (17), 354 (28), 195 (100)

				C ₂₆ H ₂₆ N ₂ OCl ₂ ESI 455 (57), 453 (75), 396 (7), 394 (10), 237 (73), 235 (100)
	OH			C ₂₉ H ₃₁ N ₂ O ₃ F ₃ :HCl FAB 497.2 (507), 195.1 (100)
				C ₂₄ H ₃₂ N ₂ O:HCl ESI 365 (100), 219 (31), 160 (23)
				C ₂₇ H ₃₀ N ₂ O:HCl ESI 399 (60), 181 (100)
				C ₂₉ H ₃₄ N ₂ O:HCl ESI 427 (41), 195 (100)
				C ₃₀ H ₃₆ N ₂ O:HCl ESI 441 (47), 195 (100)
				C ₂₈ H ₃₂ N ₃ O:HCl ESI 428 (41), 195 (100)
	OH			C ₂₇ H ₃₀ Cl ₂ N ₂ O FAB 469.2 (30), 235.1 (100)
	OH			C ₂₈ H ₃₂ Cl ₂ N ₂ O ₃ S CI 549.15 (69), 548.15 (37), 547.15 (100)
	OH			C ₂₈ H ₃₂ Cl ₂ N ₂ O ₃ S FAB 549 (60), 547.1 (87)
	OH			C ₂₇ H ₃₀ Cl ₂ N ₂ O ₃ S FAB 535 (78), 533 (100)
	OH			C ₂₆ H ₂₈ Cl ₂ N ₂ O ₃ S FAB 523 (25)
	OH			C ₃₀ H ₃₅ Cl ₂ N ₃ O FAB 524.40(20), 330.3 (100)

	OH			C ₃₆ H ₃₉ Cl ₂ N ₃ O FAB 600.5 (50), 330.4 (70)
	OH			C ₂₅ H ₂₇ BrN ₂ O FAB 453.2 (100), 245 (100)
	OH			C ₂₅ H ₂₆ N ₂ F ₂ O FAB 410.2 (25), 409.2 (100), 203.2 (50)
	OH			C ₂₇ H ₃₂ N ₂ O FAB 401.2 (95), 195 (100)
	OH			C ₂₅ H ₂₆ Cl ₂ N ₂ O 441.1 (40), 235 (42), 157 (100)
	OH			C ₂₅ H ₂₇ NO ₂ CI 374.25 (52), 356.2 (100), 178.25 (40), 160.25 (57)
	OH			C ₂₅ H ₂₅ NO ₃ FAB 388.23 (100), 210.8 (21), 168.28 (20)
	OH		-(CH ₂) ₄ CH ₃	C ₂₄ H ₃₄ N ₂ O FAB 368.3 (30), 367.3 (100)
	OH		-(CH ₂) ₃ CH ₃	C ₂₃ H ₃₂ N ₂ O GAB 353.3 (100)
	OH			C ₂₅ H ₂₆ N ₂ F ₂ O FAB 410.6 (35), 409.4 (98), 203.1 (65)
	OH			C ₂₆ H ₂₈ Cl ₂ N ₂ O FAB 457.3 (70), 455.3 (100), 237 (30), 235.1 (52)
	OH	H		C ₁₉ H ₂₃ N ₂ OCl FAB 331.2 (100),
	OH			C ₂₇ H ₃₂ N ₂ O FAB 402.1 (20.46), 401.1 (44.89), 195.1 (100)


















	OH			C ₂₅ H ₂₇ ClN ₂ O ES 409.2 (55), 408.2 (45), 407.2 (95)
	OH			C ₂₆ H ₃₀ N ₂ O ES 387 (100)
	OH			C ₂₅ H ₂₅ NO ₂ CI 372.15 (100), 354.15 (38), 195.15 (37)
	OH			C ₂₆ H ₂₉ NO ₃ FAB 404.3 (100), 227.1 (70)
	OH	H		C ₂₁ H ₃₄ N ₂ O FAB 331.4 (100), 266.2 (20)
	OH	CH ₃ (CH ₂) ₃ -		C ₂₄ H ₃₄ N ₂ O FAB 367.2 (100)
	OH			C ₂₇ H ₃₂ N ₂ O ES 401.1 (46), 195.1 (100)
	OH			C ₃₁ H ₃₈ N ₂ O ₃ ES 487 (100)
				C ₂₇ H ₂₉ Cl ₂ N ₃ O ESI 484.2 (72), 482.2 (100), 237 (60), 235.0 (65)
				C ₂₆ H ₂₇ Cl ₂ N ₃ O ESI 470.1 (80), 468.1 (100), 235 (78)
				C ₂₆ H ₂₇ Cl ₂ N ₃ O ESI 470.2 (78), 468.2 (90), 237.0 (65), 235 (100)
				C ₂₉ H ₃₅ N ₃ O ESI 442.3 (100)
	OH			C ₂₅ H ₂₆ N ₂ OBr ₂ ESI 533 (55), 531 (100), 324.8 (30)



















Table 5



wherein R¹¹, Z¹ and Z² are as defined in the following table, wherein Ac is acetyl, Me is methyl and Et is ethyl:

R ¹¹	CH(Z ¹)(Z ²)	Physical Data
H	Benzhydryl	
	Benzhydryl	C ₃₂ H ₃₇ N ₃ O:HCl CI 480 (100), 167.25 (22)
	Benzhydryl	C ₂₉ H ₃₁ N ₃ O ₃ :HCl CI 470.15 (100), 167.25 (25)
	Benzhydryl	C ₂₉ H ₃₁ N ₃ O:HCl CI 438.20 (100), 167.25 (29)
	Benzhydryl	C ₃₀ H ₃₃ N ₃ O:HCl FAB 452.3 (100), 167.0 (92)
	Benzhydryl	C ₂₉ H ₃₃ N ₃ O:HCl CI 440.20 (100), 167.25 (22)
Me	Benzhydryl	C ₂₆ H ₂₇ N ₃ O:HCl CI 398.15 (100), 167.25 (39)
Ethyl	Benzhydryl	C ₂₇ H ₂₉ N ₃ O:HCl CI 412.15 (100), 167.25 (32)
n propyl	Benzhydryl	C ₂₈ H ₃₁ N ₃ O:HCl ESI 426.1(14), 167 (100)
n butyl	Benzhydryl	C ₂₉ H ₃₃ N ₃ O:HCl ESI 440.10 (100), 167.10 (33)
isopropyl	Benzhydryl	C ₂₆ H ₃₁ N ₃ O:HCl ESI 446.10 (28), 167. (100)
	Benzhydryl	C ₂₈ H ₃₁ N ₃ O ₂ :HCl ESI 442.10 (15), 167. (100)
	Benzhydryl	C ₂₇ H ₂₉ N ₃ O ₂ :HCl FAB 428.3 (65), 232.1 (57)
H		C ₂₃ H ₂₉ N ₃ O:HCl ESI 364.1 (58), 218.1 (100)

		$C_{25}H_{33}N_3O_2 \cdot HCl$ ESI 408.1 (93), 262.1 (100)
n pentyl	Benzhydryl	$C_{30}H_{35}N_3O \cdot HCl$ ESI 454.1 (46), 167.1 (100)
n-hexyl	Benzhydryl	$C_{31}H_{37}N_3O \cdot HCl$ ESI 468.1 (26), 167 (100)
	Benzhydryl	$C_{28}H_{31}N_3O_2 \cdot HCl$ ESI 442.10 (15), 167 (100)
		$C_{31}H_{35}N_3O \cdot HCl$ ESI 466.1 (44), 181.1 (100)
		$C_{29}H_{33}N_3O_2 \cdot HCl$ ESI 456.1 (48), 181.10(100)
H		$C_{24}H_{31}N_3O \cdot HCl$ CI 378.25 (100), 306.20 (22), 218.20 (24)
H		$C_{26}H_{27}N_3O \cdot HCl$ ESI 398.10 (44), 181.1 (100)
		$C_{27}H_{33}N_3O \cdot HCl$ ESI 416.10(36), 286.1 (39)
		$C_{30}H_{31}N_3OCl_2 \cdot HCl$ ESI 522.1 (79), 521.1 (48), 520 (100)
	Benzhydryl	$C_{30}H_{34}N_2O \cdot HCl$ CI 439.25 (100), 168.30 (20)
H		$C_{27}H_{29}N_3O \cdot HCl$ CI 412.20(32), 218.20 (42), 195.35 (100)
	Benzhydryl	$C_{29}H_{31}N_3O_3 \cdot HCl$ ESI 470.1 (100), 167.1 (77.40)
H		$C_{25}H_{23}N_3Cl_2O \cdot HCl$ ESI 452.1 (100), 235 (85)

		$C_{30}H_{33}N_3O_2Cl_2:HCl$ ESI 525.1 (39), 524.1 (82), 522 (100)
		$C_{28}H_{29}N_3OCl_2:HCl$ ESI 511.1 (46), 510 (100), 514 (20), 513.1 (33.50)
		$C_{32}H_{39}N_3O:HCl$ ESI 482.1 (48), 195.1 (100)
		$C_{30}H_{35}N_3O_2:HCl$ ESI 471.1 (13), 470.1 (30), 195.1 (100)
H		$C_{25}H_{24}N_3OCl:HCl$ FAB 420.2 (35), 418.2 (100), 201.0 (75)
H		$C_{25}H_{24}N_3OF:HCl$ Elemental Analysis C: 68.12; H: 5.83; N: 9.48; Cl: 8.21; F: 4.59
	Benzhydryl	$C_{28}H_{32}N_4O:HCl$ ESI 442.1 (39), 441.1 (92), 167 (100)
	Benzhydryl	$C_{29}H_{34}N_4O:HCl$ ESI 455.1 (100), 290.1 (14), 289.1 (57.88), 167 (94)
	Benzhydryl	$C_{27}H_{30}N_4O:HCl$ ESI 428.1 (42), 427.1(97), 167 (100)
	Benzhydryl	$C_{30}H_{36}N_4O.HCl$ ESI 470.1 (48), 469 (100), 303 (93), 167 (82.75)
	Benzhydryl	$C_{29}H_{34}N_4O:HCl$ ESI 457.1(13), 456 (57), 455.1 (100), 167 (72)
	Benzhydryl	$C_{28}H_{29}N_3O_3$ FAB 456.2 (78), 167.0 (100)
		$C_{22}H_{23}Cl_2N_3O_3$ FAB 450.1 (27), 448.0 (100)
































H		$C_{24}H_{31}N_3O$ FAB 378.4 (100), 218.2 (30)
	Benzhydryl	$C_{31}H_{35}N_3O_3$ 498.2 (100), 167.1 (90)
	Benzhydryl	$C_{29}H_{31}N_3O_3$ ESI 470.1 (100), 167.1 (55)
		$C_{23}H_{27}Cl_2N_3O$ ESI 434.1 (80), 432.1 (100)
		$C_{22}H_{25}Cl_2N_3O_2$ ESI 436.1 (58), 434.1 (100)
		$C_{23}H_{27}Cl_2N_3O$ ESI 434.1 (35), 432.1 (100)
		$C_{24}H_{27}Cl_2N_3O$ ESI 446.1 (77), 444.1 (100)
		$C_{21}H_{22}Cl_2N_4O_2$ FAB 435.1 (78), 433.1 (100)





















Table 6



wherein R_{11} , Z^1 and Z^2 are as defined in the following table:

R^{11}	$CH(Z^1)(Z^2)$	Physical Data
H	Benzhydryl	
	Benzhydryl	$C_{29}H_{33}N_3O$ ESI: 440 (100) 167 (80)
	Benzhydryl	$C_{29}H_{31}N_3O$ ESI: 438 (100) 167 (99)
	Benzhydryl	$C_{30}H_{35}N_3O$ ESI: 454 (100) 167 (94)

























	Benzhydryl	$C_{29}H_{29}N_3O$ ESI: 436 (99) 167 (100)
CH ₃	Benzhydryl	$C_{27}H_{29}N_3O$ FAB: 412 (100)
	Benzhydryl	$C_{28}H_{31}N_3O$ FAB: 426 (100)
	Benzhydryl	$C_{30}H_{33}N_3O_3$ FAB: 484 (7) 261 (14) 167 (100)
	Benzhydryl	$C_{30}H_{33}N_3O$ ESI: 452 (100) 167 (60)
	Benzhydryl	$C_{33}H_{39}N_3O$ ESI: 494 (100) 167 (30)
	Benzhydryl	$C_{31}H_{35}N_3O \cdot HCl$ FAB: 466 (100)
	Benzhydryl	$C_{30}H_{33}N_3O_3 \cdot HCl$ FAB: 484 (100) 167 (41)
	Benzhydryl	$C_{33}H_{38}N_4O_2 \cdot HCl$ FAB: 523 (100)
H		$C_{26}H_{25}N_3F_2O \cdot HCl$ ESI: 434 (29) 203 (100)
H		$C_{26}H_{25}N_3F_2O \cdot HCl$ Cl: 434 (100)
H		$C_{26}H_{26}N_3ClO \cdot HCl$ ESI: 432 (60) 201 (100)
	Benzhydryl	$C_{29}H_{33}N_3O \cdot HCl$ ESI: 440 (100) 167 (89)
	Benzhydryl	$C_{33}H_{37}N_3O_2 \cdot HCl$ ESI: 508 (100) 167 (35)
H		$C_{24}H_{30}N_3ClO \cdot HCl$ ESI: 412 (100) 232 (92)

H		$C_{24}H_{31}N_3O \cdot HCl$ ESI: 378 (100) 232 (82)
H		$C_{21}H_{24}N_3ClO \cdot HCl$ ESI: 370 (86) 265 (100)
H		$C_{24}H_{30}N_3FO \cdot HCl$ ESI: 396 (31) 232 (100)
H		$C_{24}H_{30}N_3BrO \cdot HCl$ ESI: 456 (39) 232 (100)
H		$C_{25}H_{33}N_3O \cdot HCl$ ESI: 392 (73) 232 (100)
H		$C_{25}H_{31}N_3O \cdot HCl$ FAB: 390 (100)
		$C_{28}H_{39}N_3O \cdot HCl$ ESI: 434 (68) 288 (100)
		$C_{31}H_{43}N_3O \cdot HCl$ ESI: 474 (90) 328 (100)
		$C_{27}H_{37}N_3O \cdot HCl$ ESI: 420 (81) 274 (100)
H		$C_{27}H_{29}N_3O \cdot HCl$ FAB: 412 (25) 181 (100)
		$C_{29}H_{41}N_3O \cdot HCl$ ESI: 448 (97) 288 (100)
		$C_{27}H_{37}N_3O \cdot HCl$ ESI: 420 (62) 274 (100)
		$C_{28}H_{39}N_3O \cdot HCl$ ESI: 434 (66) 274 (100)
H		$C_{25}H_{33}N_3O \cdot HCl$ ESI: 392 (59) 232 (100)

























		$C_{31}H_{37}N_3O \cdot HCl$ ESI: 468 (100) 322 (92)
		$C_{28}H_{39}N_3O \cdot HCl$ ESI: 434 (100) 274 (86)
H		$C_{22}H_{25}N_3O_3 \cdot HCl$ CI: 380 (100)
		$C_{32}H_{39}N_3O \cdot HCl$ ESI: 482 (100) 322 (78)
H		$C_{21}H_{25}N_3O_2 \cdot HCl$ FAB: 352 (100)
		$C_{33}H_{41}N_3O \cdot HCl$ FAB: 496 (100)
H		$C_{26}H_{31}N_3O \cdot HCl$ ESI: 426 (19) 195 (100)
H		$C_{26}H_{26}N_3Cl_2O \cdot HCl$ ESI: 466 (79) 235 (100)
H		$C_{25}H_{32}N_4O_2 \cdot HCl$ ESI: 421 (40) 190 (100)
H		$C_{26}H_{26}N_3FO \cdot HCl$ FAB: 416 (100)
H		$C_{26}H_{25}N_3Cl_2O \cdot HCl$ ESI: 466 (100) 235 (60)
H		$C_{26}H_{26}N_3ClO \cdot HCl$ ESI: 432 (48) 201 (100)
H		$C_{26}H_{26}N_3F_2O \cdot HCl$ ESI: 434 (69) 203 (100)
		$C_{29}H_{37}N_3O \cdot HCl$ ESI: 444 (52) 326 (100)

		$C_{27}H_{33}N_3O \cdot HCl$ ESI: 416 (33) 300 (100)
		$C_{28}H_{29}N_3Cl_2O_2 \cdot HCl$ ESI: 510 (100)
		$C_{31}H_{33}N_3Cl_2O_2 \cdot HCl$ ESI: 550 (100)
		$C_{30}H_{33}N_3Cl_2O \cdot HCl$ ESI: 522 (100)
		$C_{31}H_{35}N_3Cl_2O \cdot HCl$ ESI: 536 (100)
		$C_{29}H_{29}N_3Cl_2O_3 \cdot HCl$ FAB: 538 (100)
		$C_{29}H_{31}N_3Cl_2O_2 \cdot HCl$ ESI: 524 (100)
		$C_{32}H_{36}N_4Cl_2O \cdot HCl$ FAB: 563 (100) 235 (55)
		$C_{27}H_{37}N_3O_2 \cdot HCl$ FAB: 436 (100)
		$C_{24}H_{31}N_3O_3 \cdot HCl$ FAB: 410 (100)
		$C_{25}H_{33}N_3O_2 \cdot HCl$ FAB: 408 (100)
		$C_{26}H_{35}N_3O_2 \cdot HCl$ FAB: 422 (100)
		$C_{29}H_{32}N_4Cl_2O \cdot 2HCl$ FAB: 523 (100)
		$C_{31}H_{36}N_4Cl_2O \cdot 2HCl$ FAB: 551 (100)

		$C_{30}H_{34}N_4Cl_2O \cdot 2HCl$ FAB: 537 (100)
		$C_{30}H_{34}N_4Cl_2O \cdot 2HCl$ FAB: 537 (100)
		$C_{29}H_{38}N_4O \cdot 2HCl$ FAB: 459 (100)
		$C_{33}H_{38}N_4Cl_2O \cdot 2HCl$ ESI: 577 (56) 343 (100)
		$C_{33}H_{38}Cl_2N_4O$ ESI 577 (100), 343 (45)
		$C_{33}H_{38}Cl_2N_4O$ ESI 577 (100), 343 (45)
		$C_{34}H_{40}Cl_2N_4O$ ESI 591 (100), 357 (81)
		$C_{31}H_{44}N_4O$ ESI 487 (100), 327 (51)
		$C_{33}H_{39}Cl_2N_5O$ ESI 592 (100), 358 (71), 235 (64)
		$C_{31}H_{34}Cl_2N_4O$ ESI 549 (100), 315 (52)
		$C_{31}H_{42}N_4O$ ESI 487 (100), 329 (85)
		$C_{31}H_{44}N_4O$ ESI 489 (100), 331 (99)
		$C_{33}H_{38}Cl_2N_4O_2$ ESI 593 (100), 359 (45), 297 (45)

		$C_{34}H_{40}Cl_2N_4O$ ESI 591 (100), 357 (82), 235 (99)
		$C_{34}H_{39}Cl_2N_5O_2$ ESI 620 (100), 386 (12), 235 (28)
		$C_{32}H_{38}Cl_2N_4O$ ESI 565 (100), 331 (56), 235 (52)
		$C_{32}H_{36}Cl_2N_4O_2$ ESI 579 (100), 345 (51), 235 (76)
		$C_{33}H_{38}Cl_2N_4O_2$ ESI 593 (100), 359 (63), 235 (90)
		$C_{35}H_{42}Cl_2N_4O$ ESI 605 (100), 371 (83)
		$C_{37}H_{44}Cl_2N_4O_3$ FAB 663 (100), 234 (42)
		$C_{25}H_{32}Cl_2N_4O_2$ ESI 491 (100), 333 (29)
		$C_{26}H_{32}Cl_2N_4O$ ESI 487 (100), 319 (31)
		$C_{26}H_{34}Cl_2N_4O$ ESI 489 (100), 331 (18)
		$C_{32}H_{46}N_4O_2$ ESI 519 (91), 361 (100)
		$C_{25}H_{32}N_4Cl_2O$ ESI 475 (100), 317 (24), 159 (69)

		$C_{28}H_{38}N_4O$ FAB 447.3 (100), 289.2 (25), 242.2 (36)
		$C_{29}H_{40}N_4O$ FAB 461.2 (100), 303.2 (20)
		$C_{31}H_{42}N_4O_2$ ESI 503.1 (100), 345.1 (95)
		$C_{30}H_{42}N_4O$ ESI 475.1 (99), 317.1 (100)
		$C_{30}H_{42}N_4O$ ESI 475.1 (89), 317.1 (100)
		$C_{33}H_{48}N_4O_2$ ESI 519.1 (95), 361.1 (100)256.1 (12)
		$C_{29}H_{40}N_4O_2$ ESI 477.1 (100), 319.1 (100)
		$C_{31}H_{42}N_4O$ ESI 487.10 (100), 329.1 (88)
		$C_{28}H_{38}N_4O$ FAB 447 (100), 391 (30), 317 (20)
		$C_{29}H_{41}N_5O$ FAB 476 (100), 346 (40)
		$C_{29}H_{40}N_4O$ FAB 461 (100), 391 (40), 167 (22)
		$C_{28}H_{38}N_4O$ FAB 447 (100), 391 (60)

		$C_{31}H_{42}N_4O$ ESI 487.1 (100), 329.1 (86)
		$C_{30}H_{42}N_4O_2$ ESI 491.1 (63), 333.10 (100)
		$C_{34}H_{48}N_4O$ ESI 529.1 (79), 371.1 (100)
		$C_{31}H_{45}N_5O$ ESI 504.1 (99), 358.1 (100)
		$C_{32}H_{45}N_5O$ ESI 516.1 (92), 358.1 (100), 251.1 (28)
		$C_{25}H_{32}Cl_2N_4O$ ESI 475 (100), 317 (16)
		$C_{24}H_{30}Cl_2N_4O$ ESI 461 (100), 303 (25)
		$C_{23}H_{28}Cl_2N_4O$ ESI 447 (100), 224 (64)
		$C_{26}H_{34}Cl_2N_4O$ ESI 489 (100), 331 (33)
		$C_{27}H_{25}F_4N_3O$ ESI 484 (100)
		$C_{26}H_{32}Cl_2N_4O$ ESI 487 (100), 433 (39)
		$C_{26}H_{32}Cl_2N_4O$ ESI 487 (100), 433 (46)

		$C_{31}H_{44}N_4O$ ESI 489.1 (100), 331.1 (68)
		$C_{30}H_{40}N_4O$ ESI 473.1 (100), 315.1 (55)
		$C_{32}H_{46}N_4O$ ESI 503.1 (100), 345.1 (834)
		$C_{33}H_{46}N_4O$ ESI 515.1 (73), 357.1 (100), 258.1 (9)
		$C_{32}H_{40}N_4OS$ ESI 433.1 (22), 371.1 (83)
		$C_{32}H_{44}N_4O$ ESI 501.1 (80), 343.1 (100), 251.1 (7), 159.1 (69)
		$C_{32}H_{40}N_4O_2$ ESI 513.1 (87), 433.1 (32), 355.1 (100), 275.1 (12)
		$C_{34}H_{42}N_4O$ ESI 523.1 (91), 365.1 (100)
		$C_{32}H_{38}Cl_2N_4O$ ESI 565 (100), 331 (56), 235 (52)
H		$C_{26}H_{27}N_3O$ ESI 398 (100), 397 (4)
		$C_{26}H_{34}FN_4O$ ESI 457 (92), 229 (100)
		$C_{29}H_{40}N_4O$ ESI 461 (99), 231 (100)

		$C_{30}H_{42}N_4O_2$ ESI 491.1 (90), 331.1 (65), 61 (100)
		$C_{31}H_{43}ClN_4O$ ESI 525.1 (42), 524.1 (53), 523.1 (65), 331.1 (60), 193.1 (100)
		$C_{28}H_{38}N_4O_2$ ESI 463 (100), 331 (38)
		$C_{29}H_{40}N_4O_3$ ESI 494 (100), 247 (95)
		$C_{26}H_{34}Cl_2N_4O$ ESI 491(86) 489 (100), 245 (72)
		$C_{28}H_{38}N_4O$ ESI 447 (88), 224 (100)
		$C_{26}H_{35}ClN_4O$ ESI 455 (100), 228 (85)
		$C_{26}H_{35}ClN_4O$ ESI 455 (100), 228 (60)
		$C_{24}H_{31}ClN_4O$ ESI 427 (100), 303 (10), 214 (48)
		$C_{23}H_{29}BrN_4O$ ESI 459 (99), 457 (100), 230 (45)
		$C_{26}H_{35}BrN_4O$ FAB 501 (99), 499 (100), 235 (40)
		$C_{26}H_{35}BrN_4O$ FAB 501 (99), 499 (100), 171 (28)

		$C_{26}H_{35}BrN_4O$ FAB 499(99), 497 (100), 171 (20)
		$C_{26}H_{33}FN_4O$ FAB 439 (100), 220 (7)
		$C_{26}H_{35}FN_4O$ FAB 439 (100), 220 (40)
H		$C_{21}H_{25}N_3O$ FAB 336 (100), 171 (100)
		$C_{23}H_{29}FN_4O$ FAB 397 (100), 242 (100)
		$C_{24}H_{31}FN_4O$ FAB 411 (100), 242 (90)
H		$C_{19}H_{27}N_3O$ FAB 314 (100), 247 (7)
		$C_{29}H_{39}FN_4O$ ESI 479.1(100), 424.1 (31), 331.1 (43), 203.1 (61)
		$C_{29}H_{39}FN_4O$ ESI 479.1(100), 424.1 (11), 331.1 (39), 203.1 (38)
		$C_{29}H_{39}ClN_4O$ ESI 495.1 (70), 345.1 (37), 65.0 (100)
H		$C_{24}H_{25}N_3O$ ESI 372.1 (100), 200.1 (4)
		$C_{30}H_{38}N_4O$ ESI 471.1 (100), 331.1 (36)
H		$C_{20}H_{29}N_3O$ ESI 328 (100)





































H		$C_{21}H_{31}N_3O$ ESI 342 (100)
H		$C_{22}H_{33}N_3O$ ESI 356.1 (100), 171.1 (5)
		$C_{24}H_{37}N_3O$ ESI 370.1 (100), 247.1 (20)

Table 7
compounds of the formulas shown, wherein Ph is phenyl

Compound	Physical Data
	$C_{25}H_{27}NO \cdot HCl$ ESI 358.1 (44.50), 167.0 (100)
	$C_{25}H_{27}NO \cdot HCl$ FAB 358.2 (100), 232.1 (23.70)
	$C_{27}H_{29}NO \cdot HCl$ CI 348.20 (58), 366.25 (48)
	$C_{26}H_{27}NO \cdot HCl$ FAB 370.1 (100), 167.0 (100)
	$C_{28}H_{31}NO \cdot HCl$ FAB 398.1 (100), 195.1 (98)
	$C_{26}H_{25}NOCl_2 \cdot HCl$ FAB 440.1 (65), 438.0 (100), 236.9 (38), 234.9 (60)
	$C_{25}H_{23}NO_2 \cdot HCl$ FAB 370.2 (100), 292.2 (18)

	C ₂₅ H ₂₅ NO.HCl ESI 356.1 (14.77), 168 (20.98), 167 (100)
	C ₂₆ H ₂₇ N.HCl ESI 354.1 (55.06), 167.1 (100),
	C ₂₆ H ₂₅ N.HCl ESI 352.1 (41.94), 167.1 (100)
	C ₂₅ H ₂₅ NO ₂ .HCl ESI 372.1 (15.42), 167 (100)
	C ₂₆ H ₂₇ NO ₂ .HCl CI 386.10 (73), 354.05 (88), 167.25 (100),
	C ₂₅ H ₂₄ N ₃ Cl.HCl CI 402 (55), 366.20 (77), 250.15 (34), 167.25 (100),
	C ₂₄ H ₂₇ N ₃ O.HCl CI 398.05 (100), 232.10 (19), 167.25 (74),
	C ₂₅ H ₂₆ N ₂ CI 356.2 (26) 355.2 (100), 167(28)
	C ₂₆ H ₂₅ N ₃ O ₂ .HCl ESI 412 (20), 167.1 (100)
	C ₂₆ H ₂₅ F ₂ NO ESI 406.1 (100), 203.1 (89.11)

	$C_{26}H_{26}ClNO$ ESI 406.1 (34.35), 404.10 (81.42), 201.10 (100)
	$C_{27}H_{29}NO$ ESI 384.1 (54.52), 181 (100)
	$C_{27}H_{28}Cl_2N_2O$ ESI 399.1 (13.87), 398.1 (56.98), 397.1 (100)
	$C_{26}H_{26}FNO$ ESI 388.2 (90), 185.0 (100)
	$C_{29}H_{34}N_2O$ ESI 429.1 (8.33), 428.10 (36.55), 427.1 (74.28)
	$C_{24}H_{31}NO$ FAB 350.4 (100), 204.3 (18)
	$C_{25}H_{33}NO$ FAB 364.40 (100), 204.3 (20)

	$C_{27}H_{28}F_2N_2O$ FAB 435.2 (100), 203.1 (55)
	$C_{26}H_{26}BrNO$ FAB 448.1 (100), 247.0 (58), 166.1 (38)
	$C_{26}H_{25}Br_2NO$ ESI 528 (100), 325.1 (54.35)
	$C_{27}H_{28}Br_2N_2O$ FAB 560 (20), 557 (100), 324.8 (60)
	$C_{27}H_{27}NO_3$ CI 414.20 (100), 396.20 (34), 211.15 (47), 186.15 (30)
	$C_{19}H_{19}N_3O$ ESI 306.1 (100)
	$C_{21}H_{29}N_3O$ ESI 341.1 (30.27), 340.1 (100)
	$C_{23}H_{33}N_3O$ ESI 369.1 (39.66), 368.1 (100)











	$C_{28}H_{31}NO_3$ ESI 430.1 (100), 204.1 (52.46)
	$C_{28}H_{27}NO_3$ FAB 426.3 (100), 225.0 (18), 195 (18)
	$C_{30}H_{35}NO$ ESI 426.1 (100), 408 (11), 223.0 (43)
	$C_{28}H_{31}NO_3$ ESI 430.1 (100), 412.1 (11.0), 227.0 (24.2)
	$C_{25}H_{33}NO$ ESI 364.10 (100), 346 (7)
	$C_{21}H_{23}NO_3$ FAB 338.1 (100)
	$C_{21}H_{21}F_4NO_2$ ESI 396.1 (100)
	$C_{22}H_{27}NO_3$ CI 354 (100), 336 (78)
	$C_{21}H_{21}F_4NO$ ESI 380.1 (100)

Table 8



wherein Z¹ and Z² are as defined in the following table:

Z ¹	Z ²	Physical Data
		C ₂₅ H ₂₄ N ₂ O.HCl FAB 369.2 (75), 167.1 (100)
		C ₂₇ H ₂₈ N ₂ O.HCl FAB 397.2 (40), 195.1 (100)
		C ₂₆ H ₂₆ N ₂ O.HCl ESI 383.1 (11.64), 181.1 (100)
		C ₂₅ H ₂₄ N ₂ Cl ₂ O.HCl ESI 441.1 (11.05), 440.1 (15.61), 439.1 (48.02), 438.1 (23.94), 437.1 (64.05), 235.1 (100)
		C ₂₅ H ₂₂ N ₂ OF ₂ .HCl FAB 405.2 (100), 203.1 (76)
		C ₂₅ H ₂₃ ClN ₂ O.HCl FAB 403.1 (100) 201(70)

5 ASSAYS

Nociceptin binding assay









- CHO cell membrane preparation expressing the ORL-1 receptor (2 mg) was incubated with varying concentrations of [¹²⁵I][Tyr¹⁴]nociceptin (3-500 pM) in a buffer containing 50 mM HEPES (pH7.4), 10 mM NaCl, 10 1mM MgCl₂, 2.5 mM CaCl₂, 1 mg/ml bovine serum albumin and 0.025% bacitracin. In a number of studies, assays were carried out in buffer 50 mM tris-HCl (pH 7.4), 1 mg/ml bovine serum albumin and 0.025% bacitracin. Samples were incubated for 1h at room temperature (22°C). Radiolabelled ligand bound to the membrane was harvested over GF/B 15 filters presoaked in 0.1% polyethyleneimine using a Brandell cell

harvester and washed five times with 5 ml cold distilled water.







Nonspecific binding was determined in parallel by similar assays performed in the presence of 1 μ M nociceptin. All assay points were performed in duplicates of total and non-specific binding.







5 Calculations of K_i were made using methods well known in the art.

For compounds of this invention, K_i values were determined to be in the range of 0.6 to 3000 nM, with compounds having a K_i value less than 10 nM being preferred. K_i values for representative compounds of the invention are as follows:

Compounds	K_i (nM)
	13
	200
	60
	0.6
	2.3
	77
	18
	3,000


Using the procedures described in the European Journal of Pharmacology, **336** (1997), p. 233-242, the agonist activity of compounds of the invention was determined:

Compound	% Stimulation of [³⁵ S]-GTPγS binding to human ORL-1 receptor @ 100 nM
	77
	43
	59
	102
	71
	43


	15
	95
	107
	120
	70
	101

EXAMPLE 12**Cough Studies**

The effects of nociceptin agonist Compound A (0.3 - 10 mg/kg, p.o.) and Compound B (10 mg/kg, p.o.)



COMPOUND A



COMPOUND B

- were evaluated in capsaicin-induced cough in the guinea pig according to the methods of Bolser et al. British Journal of Pharmacology (1995) 114, 735-738. This model is a widely used method to evaluate the
- 5 activity of potential antitussive drugs. Overnight fasted male Hartley guinea pigs (350-450 g, Charles River, Bloomington, MA, USA) were placed in a 12" x 14" transparent chamber. The animals were exposed to aerosolized capsaicin (300 μ M, for 4 min) produced by a jet nebulizer (Puritan Bennett, Lenexa, KS, USA) to elicit the cough reflex. Each
- 10 guinea pig was exposed only once to capsaicin. The number of coughs were detected by a microphone placed in the chamber and verified by a trained observer. The signal from the microphone was relayed to a polygraph which provided a record of the number of coughs. Either vehicle (methylcellulose 1 ml/kg, p.o.) or Compound A or Compound B
- 15 were given 2 hours before aerosolized capsaicin. The antitussive activity of baclofen (3 mg/kg, p.o.) was also tested as a positive control. The results are summarized in the bar graph in Fig. 1.

EXAMPLE 13

20 Respiratory Measurements

- Studies were performed on male Hartley guinea pigs ranging in weight from 450 to 550 g. The animals were fasted overnight but given water and libitum. The guinea pigs were placed in a whole-body, head-out plethysmograph and a rubber collar was placed over the animal's
- 25 head to provide an airtight seal between the guinea pig and the plethysmograph. Airflow was measured as a differential pressure across a wire mesh screen which covered a 1-in hole in the wall of the plethysmograph. The airflow signal was integrated to a signal proportional to volume using a preamplifier circuit and a pulmonary

function computer (Buxco Electronics, Sharon, CT., model XA). A head chamber was attached to the plethysmograph and air from a compressed gas source (21%O₂, balance N₂) was circulated through the head chamber for the duration of study. All respiratory measurements were made while the guinea pigs breathed this circulating air.

The volume signal from each animal was fed into a data acquisition/analysis system (Buxco Electronics, model XA) that calculated tidal volume and respiratory rate on a breath-by-breath basis. These signals were visually displayed on a monitor. Tidal volume and respiratory rate were recorded as an average value every minute.

The guinea pigs were allowed to equilibrate in the plethysmograph for 30 min. Baseline measurements were obtained at the end of this 30 min period. The guinea pigs were then removed from the plethysmograph and orally dosed with Compound A from Example 12 (10 mg/kg, p.o.), baclofen (3 mg/kg, p.o.) or a methylcellulose vehicle placebo (2 ml/kg, p.o.). Immediately after dosing, the guinea pigs were placed into the plethysmograph, the head chamber and circulating air were reconnected and respiratory variables were measured at 30, 60, 90 and 120 min post treatment. This study was performed under ACUC protocol #960103.

Data Analysis

The data for tidal volume (V_T), respiratory rate (f) and minute volume ($MV = V_T \times f$) were made for the baseline condition and at each time point after the drug or vehicle. The results are expressed as the mean \pm SEM. The results are shown in Figures 2A, 2B and 2C. Fig. 2A shows the change in Tidal Volume, Fig. 2B shows the change in Tidal Volume and Fig. 2C shows the change in frequency of breaths.

We have surprisingly discovered that nociceptin receptor ORL-1 agonists exhibit anti-tussive activity, making them useful for suppressing coughing in mammals. Non-limitative examples of nociceptin receptor ORL-1 agonists include the nociceptin receptor ORL-1 agonist compounds described herein. For mammals treated for coughing, the nociceptin receptor ORL-1 agonists may be administered

along with one or more additional agents for treating cough, allergy or asthma symptoms selected from antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists.

Non limitative examples of antihistamines include: astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine (also known as SCH-34117), doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, equitazine, mianserin, noberastine, meclizine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine and triprolidine.

Non-limitative examples of histamine H₃ receptor antagonists include: thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, UCL-1199 and clozapine. Other compounds can readily be evaluated to determine activity at H₃ receptors by known methods, including the guinea pig brain membrane assay and the guinea pig neuronal ileum contraction assay, both of which are described in U.S. Patent 5,352,707. Another useful assay utilizes rat brain membranes and is described by West et al., "Identification of Two-H₃-Histamine Receptor Subtypes," *Molecular Pharmacology*, Vol. 38, pages 610-613 (1990).

The term "leukotriene inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the action or activity of leukotrienes. Non-limitative examples of leukotriene inhibitors include montelukast [R-(E)]-1[[[1-[3-[2-(7-chloro-2-quinolinyl)-ethenyl]phenyl]-3[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid and its sodium salt, described in EP 0 480 717; 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)thio) methylcyclopropaneacetic acid, and its sodium salt, described in WO 97/28797 and U.S. Patent 5,270,324; 1-(((1(R)-3(3-(2-

(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio) methyl)cyclopropaneacetic acid, and its sodium salt, described in WO 97/28797 and U.S. Patent 5,472,964; pranlukast, N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-p-(4-phenylbutoxy) benzamide) described in WO 97/28797 and EP 173,516; zafirlukast, (cyclopentyl-3-[2-methoxy-4-[(o-tolylsulfonyl) carbamoyl]benzyl]-1-methylindole-5-carbamate) described in WO 97/28797 and EP 199,543; and [2-[[2(4-*tert*-butyl-2-thiazolyl)-5-benzofuranyl] oxymethyl]phenyl]acetic acid, described in U.S. Patent 5,296,495 and Japanese patent JP08325265 A.

The term "5-lipoxygenase inhibitor" or "5-LO inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the enzymatic action of 5-lipoxygenase. Non-limitative examples of 5-lipoxygenase inhibitors include zileuton, docebenone, piriipost, ICI-D2318, and ABT 761.

Non-limitative examples of β -adrenergic receptor agonists include: albuterol, bitolterol, isoetharine, mataproterenol, perbuterol, salmeterol, terbutaline, isoproterenol, ephedrine and epinephrine.

A non-limitative example of a xanthine derivative is theophylline.

Non-limitative examples of α -adrenergic receptor agonists include arylalkylamines, (e.g., phenylpropanolamine and pseudophedrine), imidazoles (e.g., naphazoline, oxymetazoline, tetrahydrozoline, and xylometazoline), and cycloalkylamines (e.g., propylhexedrine).

A non-limitative example of a mast cell stabilizer is nedocromil sodium.

Non-limitative examples of anti-tussive agents include codeine, dextromethorphan, benzonatate, chlophedianol, and noscapine.

A non-limitative example of an expectorant is guaifenesin.

Non-limitative examples of NK₁, NK₂ and NK₃ tachykinin receptor antagonists include CP-99,994 and SR 48968.

Non-limitative examples of GABA_B agonists include baclofen and 3-aminopropyl-phosphinic acid.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers

can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.

Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 300 mg, according to the particular application.

5 The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the
10 optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be
15 regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended dosage regimen is oral administration of from 10 mg to 2000 mg/day preferably 10 to 1000 mg/day, in two to four divided doses to provide
20 relief from pain, anxiety, depression, asthma or alcohol abuse. The compounds are non-toxic when administered within this dosage range.

For treating cough, the amount of nociceptin receptor ORL-1 agonist in a unit dose is preferably from about 0.1 mg to 1000 mg, more preferably, from about 1 mg to 300 mg. A typical recommended dosage
25 regimen is oral administration of from 1 mg to 2000 mg/day, preferably 1 to 1000 mg/day, in two to four divided doses. When treating coughing, the nociceptin receptor ORL-1 agonist may be administered with one or more additional agents for treating cough, allergy or asthma symptoms selected from the group consisting of: antihistamines, 5-lipoxygenase
30 inhibitors, leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists. The nociceptin receptor ORL-1 agonist and the additional agents are preferably administered in
35 a combined dosage form (e.g., a single tablet), although they can be

- administered separately. The additional agents are administered in amounts effective to provide relief from cough, allergy or asthma symptoms, preferably from about 0.1 mg to 1000 mg, more preferably from about 1 mg to 300 mg per unit dose. A typical recommended
- 5 dosage regimen of the additional agent is from 1 mg to 2000 mg/day, preferably 1 to 1000 mg/day, in two to four divided doses.

- The following are examples of pharmaceutical dosage forms which contain a compound of the invention. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the
- 10 examples provided.

Pharmaceutical Dosage Form Examples

EXAMPLE A-Tablets

No.	Ingredients	mg/tablet	mg/tablet
1.	Active compound	100	500
2.	Lactose USP	122	113
3.	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4.	Corn Starch, Food Grade	45	40
5.	Magnesium Stearate	<u>3</u>	<u>7</u>
Total		300	700

Method of Manufacture

- Mix Item Nos. 1 and 2 in a suitable mixer for 10–15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a
- 15 coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10–15 minutes. Add Item No. 5 and mix for 1–3 minutes. Compress the mixture to appropriate size and weigh on a suitable tablet machine.

EXAMPLE B-Capsules

No.	Ingredient	mg/capsule	mg/capsule
1.	Active compound	100	500
2.	Lactose USP	106	123
3.	Corn Starch, Food Grade	40	70
4.	Magnesium Stearate NF	<u>7</u>	<u>7</u>
Total		253	700


Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

- 5 While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.


WHAT IS CLAIMED IS:

1. A compound represented by the formula




- 5 or a pharmaceutically acceptable salt or solvate thereof, wherein:
 the dotted line represents an optional double bond;
 X1 is R5-(C1-C12)alkyl, R6-(C3-C12)cycloalkyl, R7-aryl, R8-heteroaryl or R10-(C3-C7)heterocycloalkyl;
 X2 is -CHO, -CN, -NHC(=NR26)NHR26, -CH(=NOR26), -NHOR26,
 10 R7-aryl, R7-aryl(C1-C6)alkyl, R7-aryl(C1-C6)alkenyl, R7-aryl(C1-C6)-alkynyl, -(CH2)vOR13, -(CH2)vCOOR27, -(CH2)vCONR14R15, -(CH2)vNR21R22 or -(CH2)vNHC(O)R21, wherein v is zero, 1, 2 or 3 and wherein q is 1 to 3 and a is 1 or 2;

or X1 is



and X2 is hydrogen;

or X1 and X2 together form a spiro group of the formula



m is 1 or 2;

n is 1, 2 or 3, provided that when n is 1, one of R¹⁶ and R¹⁷ is -C(O)R²⁸;

p is 0 or 1;

5 Q is -CH₂-, -O-, -S-, -SO-, -SO₂- or -NR¹⁷-;

R¹, R², R³ and R⁴ are independently selected from the group consisting of hydrogen and (C₁-C₆)alkyl, or (R¹ and R⁴) or (R² and R³) or (R¹ and R³) or (R² and R⁴) together can form an alkylene bridge of 1 to 3 carbon atoms;

10 R⁵ is 1 to 3 substituents independently selected from the group consisting of H, R⁷-aryl, R⁶-(C₃-C₁₂)cycloalkyl, R⁸-heteroaryl, R¹⁰-(C₃-C₇)heterocycloalkyl, -NR¹⁹R²⁰, -OR¹³ and -S(O)₀₋₂R¹³;

R⁶ is 1 to 3 substituents independently selected from the group consisting of H, (C₁-C₆)alkyl, R⁷-aryl, -NR¹⁹R²⁰, -OR¹³ and -SR¹³;


15 R⁷ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, R²⁵-aryl, (C₃-C₁₂)cycloalkyl, -CN, -CF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -OCF₃, -NR¹⁹R²⁰, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -NHSO₂R¹⁹, -SO₂N(R²⁶)₂, -SO₂R¹⁹, -SOR¹⁹, -SR¹⁹, -NO₂, -CONR¹⁹R²⁰, -NR²⁰COR¹⁹, -COR¹⁹, -COCF₃, -OCOR¹⁹, -OCO₂R¹⁹,
20 -COOR¹⁹, -(C₁-C₆)alkyl-NHCOOC(CH₃)₃, -(C₁-C₆)alkyl-NHCOCF₃, -(C₁-C₆)alkyl-NHSO₂-(C₁-C₆)alkyl, -(C₁-C₆)alkyl-NHCONH-(C₁-C₆)-alkyl or $-(CH_2)_f-N \begin{array}{c} \diagup \diagdown \\ \diagdown \diagup \end{array} N-R^{19}$, wherein f is 0 to 6; or R⁷ substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;


25 R⁸ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halo, (C₁-C₆)alkyl, R²⁵-aryl, (C₃-C₁₂)cycloalkyl, -CN, -CF₃, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -OCF₃, -NR¹⁹R²⁰, -(C₁-C₆)alkyl-NR¹⁹R²⁰, -NHSO₂R¹⁹, -SO₂N(R²⁶)₂, -NO₂, -CONR¹⁹R²⁰, -NR²⁰COR¹⁹, -COR¹⁹, -OCOR¹⁹, -OCO₂R¹⁹ and -COOR¹⁹;

30 R⁹ is hydrogen, (C₁-C₆)alkyl, halo, -OR¹⁹, -NR¹⁹R²⁰, -NHCN, -SR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

R¹⁰ is H, (C₁-C₆)alkyl, -OR¹⁹, -(C₁-C₆)alkyl-OR¹⁹, -NR¹⁹R²⁰ or -(C₁-C₆)alkyl-NR¹⁹R²⁰;

35 R¹¹ is independently selected from the group consisting of H, R⁵-(C₁-C₆)alkyl, R⁶-(C₃-C₁₂)cycloalkyl, -(C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl,





or R^{24} R^{23} , wherein r is 0 to 3; w and u are each 0-3, provided that the sum of w and u is 1-3; c and d are independently 1 or 2; s is 1 to 5; and ring A is a fused R^7 -phenyl or R^8 -heteroaryl ring;

R^{23} is 1 to 3 substituents independently selected from the group consisting of H, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $-\text{OR}^{19}$, $-(\text{C}_1\text{-C}_6)\text{alkyl-OR}^{19}$, $-\text{NR}^{19}\text{R}^{20}$ and $-(\text{C}_1\text{-C}_6)\text{alkyl-NR}^{19}\text{R}^{20}$;


R^{24} is 1 to 3 substituents independently selected from the group consisting of R^{23} , $-\text{CF}_3$, $-\text{OCF}_3$, NO_2 or halo, or R^{24} substituents on adjacent ring carbon atoms may together form a methylenedioxy or ethylenedioxy ring;

R^{25} is 1-3 substituents independently selected from the group consisting of H, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ and halo;

R^{26} is independently selected from the group consisting of H, $(\text{C}_1\text{-C}_6)\text{alkyl}$ and $\text{R}^{25}\text{-C}_6\text{H}_4\text{-CH}_2\text{-}$;


R^{27} is H, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $\text{R}^7\text{-aryl}(\text{C}_1\text{-C}_6)\text{alkyl}$, or $(\text{C}_3\text{-C}_{12})\text{cycloalkyl}$;

R^{28} is $(\text{C}_1\text{-C}_6)\text{alkyl}$, $-(\text{C}_1\text{-C}_6)\text{alkyl}(\text{C}_3\text{-C}_{12})\text{cycloalkyl}$, $\text{R}^7\text{-aryl}$, $\text{R}^7\text{-aryl}(\text{C}_1\text{-C}_6)\text{alkyl}$, $\text{R}^8\text{-heteroaryl}$, $-(\text{C}_1\text{-C}_6)\text{alkyl-NR}^{19}\text{R}^{20}$, $-(\text{C}_1\text{-C}_6)\text{alkyl-OR}^{19}$ or $-(\text{C}_1\text{-C}_6)\text{alkyl-SR}^{19}$;



provided that when X^1 is

or X^1 and X^2 together are




and Z^1 is R^7 -phenyl, Z^2 is not hydrogen or $(\text{C}_1\text{-C}_3)\text{alkyl}$;


provided that when Z^1 , Z^2 and Z^3 , together with the carbon to which they are attached, form



or




, and X^1 and X^2 together are




, R¹¹ is not H, (C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl or (C₁-C₆)hydroxyalkyl;

provided that when R² and R⁴ form an alkylene bridge, Z¹, Z² and Z³, together with the carbon to which they are attached, are not




provided that when X¹ is cycloalkyl, Z² is not H.

- 10
2. A compound of claim 1 wherein Z¹ and Z² are each R⁷-aryl.
 3. A compound of claim 2 wherein R⁷ is selected from the group consisting of (C₁-C₆)alkyl and halo.
 - 15
 4. A compound of claim 1 wherein X¹ is R⁷-aryl and X² is OH or -NC(O)R²⁸.




5. A compound of claim 1 wherein X¹ is hydrogen.
- 20
6. A compound of claim 5 wherein R¹² is hydrogen and R¹¹ is (C₁-C₆)alkyl, -(C₁-C₆) alkyl(C₃-C₁₂)cycloalkyl, -(C₁-C₆)alkyl-OR¹⁹ or -(C₁-C₆)alkyl-NR¹⁹R²⁰.
 7. A compound of claim 1 wherein X¹ and X² together form the spirocyclic group




8. A compound of claim 7 wherein m is 1, R^{17} is phenyl and R^{16} is $-(C_1-C_6)alkyl-OR^{19}$ or $-(C_1-C_6)alkyl-NR^{19}R^{20}$.

5

9. A compound selected from the group consisting of





- 5 10. A pharmaceutical composition comprising a therapeutically effective amount of compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 10 11. A pharmaceutical composition comprising: a therapeutically effective amount of a nociceptin receptor ORL-1 agonist; a therapeutically effective amount of a second agent selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors,

- leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists; and a pharmaceutically acceptable carrier.
- 5
12. The use of a compound of claim 1 for the treatment of pain, anxiety, asthma, depression or alcohol abuse.
- 10
13. The use of a nociceptin receptor ORL-1 agonist, alone or in combination with a second agent for treating cough, allergy or asthma symptoms selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists, for the treatment of cough.
- 15
14. The use of a compound of claim 1 for the manufacture of a medicament for treating pain, anxiety, asthma, depression or alcohol abuse.
- 20
15. The use of a nociceptin receptor ORL-1 agonist, alone or in combination with a second agent for treating cough, allergy or asthma symptoms selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H₃ inhibitors, β -adrenergic receptor agonists, xanthine derivatives, α -adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK₁, NK₂ and NK₃ tachykinin receptor antagonists, and GABA_B agonists, for the manufacture of a medicament for the treatment of cough.
- 25
- 30

1/4




FIG. 1

*P<0.05 COMPARED TO CONTROLS USING AN ANOVA IN CONJUNCTION WITH A DUNNETT'S T-TEST




FIG. 2A




FIG. 2B

4/4




FIG. 2C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/14165

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/52 C07D211/58 C07D471/10 C07D401/04 A61K31/445
//(C07D471/10,235:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 195 19 245 A (BOEHRINGER INGELHEIM KG) 17 October 1996 (1996-10-17) page 4, line 63 -page 5, line 2; claims 1,10; examples 11,48 ---	1,10,14
X	US 3 311 624 A (G. OHNACKER ET AL.) 28 March 1967 (1967-03-28) column 23, line 45 - line 71; claims 1,2; examples ---	1,10,14
X	G. HENDERSON ET AL.: TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 18, August 1997 (1997-08), pages 293-300, XP004085920 page 296, compound "Lofentanyl"; page 297, table, "Lofentanyl" --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

28 October 1999

Date of mailing of the international search report

05/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 99/14165

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 121 972 A (JANSSEN PHARMACEUTICA N.V.) 17 October 1984 (1984-10-17) page 38, line 18 - line 19 ---	1
X	US 5 583 000 A (P. R. ORTIZ DE MONTELLANO ET AL.) 10 December 1996 (1996-12-10) table 1, compound code no. UCSF2, UCSF24, UCSF32, UCSF33, UCSF46, UCSF54, UCSF55, UCSF56, UCSF57, UCSF61, UCSF73 ---	1
X	EP 0 709 375 A (ZENECA LTD.) 1 May 1996 (1996-05-01) page 28, compound IX ---	1
A,P	EP 0 856 514 A (F. HOFFMANN-LA ROCHE AG) 5 August 1998 (1998-08-05) cited in the application claims 1,12,13 ---	1,7, 9-11,14
A,P	WO 98 54168 A (BANYU PHARMACEUTICAL CO., LTD.) 3 December 1998 (1998-12-03) cited in the application abstract ---	1,10,11, 14
A	US 3 318 900 A (P. A. J. JANSSEN) 9 May 1967 (1967-05-09) cited in the application column 1, line 14 - line 66 ---	1,10
A	EP 0 743 312 A (ADIR ET CIE.) 20 November 1996 (1996-11-20) examples 6,22 ---	1
A	US 4 521 537 A (R. W. KOSLEY, JR., ET AL.) 4 June 1985 (1985-06-04) tables I-III ---	1
A	WO 97 28797 A (MERCK & CO., INC.) 14 August 1997 (1997-08-14) cited in the application -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/14165

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19519245 A	17-10-1996	AU 706209 B	10-06-1999
		AU 5687496 A	30-10-1996
		BG 62138 B	31-03-1999
		BG 101947 A	29-05-1998
		BR 9604821 A	09-06-1998
		CA 2218096 A	17-10-1996
		CZ 9703257 A	17-06-1998
		WO 9632386 A	17-10-1996
		EP 0824530 A	25-02-1998
		HR 960168 A	31-08-1997
		HU 9802270 A	28-09-1999
		JP 11503441 T	26-03-1999
		NO 974734 A	13-10-1997
		PL 322768 A	16-02-1998
		SK 138797 A	04-03-1998
		US 5710155 A	20-01-1998
		US 5861509 A	19-01-1999
		ZA 9602916 A	14-10-1996
US 3311624 A	28-03-1967	CH 436290 A	
		CH 436293 A	
		FR 3846 M	
		FR 1555457 A	31-01-1969
		GB 1052302 A	
EP 121972 A	17-10-1984	AT 43336 T	15-06-1989
		AU 562186 B	04-06-1987
		AU 2670684 A	18-10-1984
		CA 1217484 A	03-02-1987
		DK 139684 A	12-10-1984
		ES 531482 A	01-08-1985
		ES 531483 A	01-08-1985
		FI 841405 A	12-10-1984
		GR 79186 A	02-10-1984
		IL 71475 A	31-12-1987
		JP 59225161 A	18-12-1984
		KR 8601904 B	24-10-1986
		NZ 207676 A	11-04-1986
		PH 22065 A	20-05-1988
		PT 78390 A, B	01-05-1984
		SU 1313344 A	23-05-1987
US 5583000 A	10-12-1996	NONE	
EP 709375 A	01-05-1996	JP 8208605 A	13-08-1996
		US 5710169 A	20-01-1998
EP 856514 A	05-08-1998	AU 5280998 A	06-08-1998
		CA 2226058 A	30-07-1998
		CN 1191862 A	02-09-1998
		CZ 9800273 A	12-08-1998
		HR 980043 A	31-12-1998
		HU 9800138 A	28-09-1998
		JP 10212290 A	11-08-1998
		NO 980332 A	31-07-1998
		PL 324571 A	03-08-1998
		ZA 9800570 A	30-07-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/14165

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9854168 A	03-12-1998	AU 7453298 A	30-12-1998
US 3318900 A	09-05-1967	BE 663433 A	05-11-1965
		DE 1545997 A	23-04-1970
		FR 1469467 A	10-05-1967
		GB 1046312 A	
EP 743312 A	20-11-1996	FR 2734265 A	22-11-1996
		AU 702587 B	25-02-1999
		AU 5229396 A	28-11-1996
		CA 2176668 A	18-11-1996
		CN 1136568 A	27-11-1996
		JP 8311067 A	26-11-1996
		NO 962043 A	18-11-1996
		NZ 286604 A	26-01-1998
		US 5698567 A	16-12-1997
		ZA 9603950 A	25-11-1996
US 4521537 A	04-06-1985	US 4405631 A	20-09-1983
		AT 33656 T	15-05-1988
		AU 576473 B	01-09-1988
		AU 1816983 A	23-02-1984
		CA 1210764 A	02-09-1986
		DE 3376327 A	26-05-1988
		DK 381983 A	21-02-1984
		EP 0102034 A	07-03-1984
		ES 525013 A	01-06-1985
		ES 540841 A	01-12-1985
		FI 832959 A	21-02-1984
		GR 78667 A	27-09-1984
		JP 59053489 A	28-03-1984
		NZ 205320 A	29-05-1987
		PH 18839 A	10-10-1985
		PT 77223 A, B	01-09-1983
		US 4472580 A	18-09-1984
		US 4577026 A	18-03-1986
		US 4569998 A	11-02-1986
		US 4579950 A	01-04-1986
		US 4668791 A	26-05-1987
		US 4695637 A	22-09-1987
		ZA 8306127 A	25-04-1984
WO 9728797 A	14-08-1997	AU 2257997 A	28-08-1997
		BG 102669 A	30-04-1999
		CA 2245162 A	14-08-1997
		CN 1210465 A	10-03-1999
		CZ 9802487 A	13-01-1999
		JP 11504044 T	06-04-1999
		NO 983641 A	07-08-1998
		PL 328074 A	04-01-1999

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 14165

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 12,13,15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/composition (Rule 39.1(iv) - Method for treatment of the human or animal body by therapy).
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.